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The introduction of nanoformulated antiretroviral therapeutic regimens is a promising
alternative to standard once a day oral treatment of HIV infection. Our lab has pioneered
this effort and was successful in harnessing mononuclear phagocytes (monocytes,
dendritic cells and macrophages) as nanoformulated drug carriers. The approach was
developed as Trojan horses for drug transport, delivery and distribution to sites of viral
replication in order to facilitate microbial elimination in HIV sanctuaries. However, the
remaining challenges for current antiretroviral nanoformulations include to formulate a
broad range of hydrophilic short-acting drugs, and to elucidate the mechanism of
sequestered nanoparticles in macrophages at the subcellular level. To this end, we
developed a two-step synthesis to create a long-acting lamivudine (2’,3’-dideoxy-3’thiacytidine, 3TC). A stable hydrophobic pro-drug crystal formulation was produced by
poloxamer drug encasement. Conversion of the hydrophilic 3TC significantly extended
its bioavailability facilitated by chemical drug conjugation to a fatty acid and creating a
myristoylated drug. A folate targeted poloxamer 407 coated a newly formed
nanocrystalline

pro-drug

markedly

improving

cell

uptake,

bioavailability

and

pharmacokinetic profiles. Reduced cytotoxicity and robust antiretroviral activities were
also achieved. The nanoparticle interactions at the subcellular level were investigated
vial nanoformulated protease inhibitor. Quantitative SWATH-MS proteomics for complete
II

recording of fragment ion peptide precursors in biological sample. and cell profiling were
applied for endolysosomal trafficking for HIV-1 assembly and nanoformulation depot
formation. We believe these findings unveil new opportunities for nanoformulated
antiretroviral therapy and have brought the idea of long-acting antiretroviral therapy
closer to the clinical translation.
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Chapter I.
Introduction
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1.1. HIV and AIDS
1.1.1. Epidemic
Human immunodeficiency virus infection and acquired immune deficiency
syndrome (HIV/AIDS) is a spectrum of conditions caused by infection with the human
immunodeficiency virus. Since its first discovery in 1981, HIV/AIDS has killed more than
25 million people worldwide. It has become a global pandemic. As of 2014,
approximately 36.9 million people are living with HIV globally, and 1.18 million people
died of HIV/AIDS. Due to the widespread infection of HIV there has been a
determination for the discovery and use of medicinal agents that can inhibit the virus.
HIV type-1 (HIV-1) displays extraordinary genetic variation and can be phylogenetically
classified into three distinct groups and several subgroups across the globe. While HIV-1
clade C dominates the HIV-1 epidemic worldwide with more than 50% of the total viral
infections, predominantly in Southern Africa, and other parts of Asia, HIV-1 subtype B is
mainly found in Europe and America with about 10% of the total infections [1, 2].
1.1.2. Pathobiology
HIV is a member of the genus Lentivirus, belonging to the family Retrovirus. HIV is
roughly spherical with a diameter of about 80 to 120 nm in diameter. It is transmitted as
single-stranded, positive-sense, enveloped RNA virus. It is composed of 2,000 copies of
the viral protein p24, which is tightly bound to nucleocapsid proteins and enzymes
including reverse transcriptase, proteases, ribonuclease and integrase. The p24 protein
is coated by capsid, which helps in ready adsorption onto the host cell surface and
provides a protective shell for the nucleic acid core. A series of host cell proteins and
viral specific glycoproteins including gp41 and gp120 are embedded in the phospholipid

2

bilayer. In addition to the viral core HIV has six regulatory genes (tat, rev, nef, vif, vpr
and vpu) that affect its abilities to infect, replicate and assemble within the cell [3, 4].
HIV primarily infects components of the human immune system such as CD4+ T
cells, monocytes, macrophages, glial cells, and dendritic cells. The HIV virion enters
host cells by the adsorption of glycoproteins on its surface to receptors on the target cell
followed by fusion of the viral envelope with the cell membranes and the release of the
HIV capsid into the cell. Entry to the cell begins through interaction of the trimeric
envelope gp160 spike with both CD4 and a chemokine receptor, either CXCR4 or
CCR5. The virus will first attach to the host cell via the CD4 receptor through the CD4
binding domains of gp120. The envelope complex undergoes a structural change,
exposing the chemokine binding domains of gp120 and allowing them to interact with the
target chemokine receptor. Fusion peptide gp41 then can penetrate the cell membrane,
causing the collapse of the extracellular portion of gp41 into a hairpin, fusion of the host
cell membranes as well as subsequent entry of the viral capsid. The HIV RNA and
various enzymes are injected into the cell. The viral single-strand RNA genome is
transcribed into double-strand DNA and integrated into a host chromosome. Infection
and ultimate destruction of CD4+ T cells heralds secondary immune deficiency and
concomitant co-morbid conditions that include opportunistic infections and primary virusinduced metabolic changes that affect also the function of the central nervous system
(CNS), gut and lymphoid tissues. Within days after primary infection HIV invades the
nervous system through lymphocytes and macrophages that cross the blood brain
barrier (BBB) and serve as Trojan Horses for viral dissemination [4, 5].

3

1.2. Macrophages and HIV reservoir
Mononuclear phagocyte including blood monocyte, tissue macrophages and
dendritic cells are principal cells involved in the clearance and inactivation of the HIV.
These cells act as the reservoirs and vehicles for the dissemination of this viral
pathogen. After binding and uptake, the ability of HIV-1 to complete its replication cycle
depends mainly on differentiation and activation of its target cell and on molecular
determinants of the infecting viral strain. The viral infection is highly dependent on the
state of macrophage differentiation and the role of macrophages is a reservoir for
persistent lentiviral infection. It will decide whether viral infection is abortive, restricted,
permissive,

latent,

or

enhanced.

Cellular

differentiation

parallels

macrophage

susceptibility to viral infection. The viral life cycle in monocytes and macrophages is
regulated by physiological factors involved in differentiation from monocyte precursors to
mature tissue macrophages [6-8].
The transmission of HIV occurs through exchange of body fluids and is mediated in
large measure by cell-associated virus. HIV-1 in leukocytes of seminal and vaginal
fluids, uterine cervix, and gastrointestinal lamina propria support a cell-mediated
transmission of virus. After primary viral exposure, high levels of HIV replication ensue in
the infected human host, which results in plasma viremia. Virus seeds tissue
macrophages and continues to replicate during the long subclinical latency period. Viral
replication is regulated by humoral and cellular immune factors. These viral-mediated
immune regulatory factors are produced against a number of HIV gene products.
Macrophage amplify production of a variety of immunoregulatory molecules such as
complement, arachidonic acid metabolites, neutral proteases, various growth factors,
and other cytokines including platelet-derived growth factor, tumor necrosis factor α
(TNF- α), colony-stimulating factors (CSFs), the interleukins, and the interferons (IFN- α
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and IFN-β). Many cytokines like interleukins (IL-1, -3, -4, and -6), macrophage and
granulocyte-macrophage CSFs (M-CSF and GM-CSF), and TNF- α up-regulate HIV
gene expression and thus play important roles in disease onset and progression. Some
cytokines like IFN-α, -β, and –γ and IL-4 exert suppressive effects on HIV replication.
The cytokine responses to viral infection complement immune-specific antiviral
responses including antibody-dependent complement-mediated, neutralization, and cellmediated immune responses.
Viral reservoir sites protect the virus from biological elimination pathways, immune
response, and antiretroviral drugs. They allow viral dissemination throughout the body,
and serve as a major source of viral rebound upon treatment failure, and contribute to
the development of drug resistance. Resting CD4+ cells are known to be the main
cellular reservoir for the latent HIV-1 infection due to their ability to persist for a long
span. Although the pool of latently infected, resting CD4+ T cells has been the most
extensively studied HIV reservoir to date and is widely recognized as one of the major
obstacles to achieving eradication of virus, low levels of HIV replication may persist in
infected individuals. The lack of consensus on the life span of the latent viral reservoir
has sparked an intense debate regarding the possibility that low levels of HIV replication
in subsets of CD4+ T cells in the lymphoid tissue may contribute to replenishment of
infected CD4+ T cells. By this mechanism, the overall half-life of the viral reservoir could
be indefinitely extended. In this regard, previous mathematical models have suggested
that productively infected CD4+ T cells have a relatively short in-vivo half-life (<1 day)
following initiation of ART. The data indicate that such cells should no longer be present
in infected individuals who had been receiving clinically effective ART for extended
periods. However, activated CD4+ T cells, enriched at high purity from the blood of a
viremic individual receiving ART, carry HIV proviral DNA and are capable of
spontaneously producing virions in culture. Furthermore, phylogenetic analyses of HIV
5

env provided evidence for virologic cross-talk between infected resting and activated
CD4+ T cells in the absence of detectable plasma viremia. HIV replicates primarily in the
lymphoid tissues with extremely high levels of viral replication and extensive destruction
of CD4+ T cells in the gut-associated lymphoid tissue (GLAT) of infected animals or
humans. The overall HIV burden is substantially higher in the GALT than in the blood of
infected individuals receiving long-term treatment [9].
Besides, other cellular reservoirs including monocytes and macrophages are the
most important reservoirs outside the blood stream, which have been described to play
an important role in HIV persistence. Monocytes and macrophages are relatively longlived cells since HIV has very low cytopathic effects on them, making them a persistent
reservoir of HIV regardless of the presence of highly active antiretroviral therapy.
Monocytes and macrophages express efflux transporters, which contribute to maintain
subtherapeutic concentrations of antiretroviral medications in these cells and may
explain why macrophages are sanctuaries for HIV. Macrophages are a major and crucial
target of HIV-1 infection and, as potential long-term HIV reservoirs, infected cells must
be selectively destroyed to achieve HIV-1 eradication. As macrophages function as
potent antigen-presenting cells and mediators of both innate and acquired immunity,
HIV-1-mediated macrophage deficiency is catastrophic to the global immune response.
A significant obstacle in clearing virus from infected individuals is multiple latently
infected viral sanctuaries. Latent HIV-1 can emerge with recrudescence as a productive
infection later in disease progression and might also represent a source for the
emergence of resistant HIV-1. Many regimens eventually fail, primarily because of lack
of adherence to strict regimens, delayed toxicities and/or the emergence of drugresistant HIV strains.
The function of macrophages in vivo presents a long-lived target for HIV-1
infection; the half-life (t1/2) of macrophages is significantly longer than that of an activated
6

lymphocyte (weeks/years versus hours/days). More specifically, the life span of activated
HIV-1-infected lymphocytes is relatively attenuated, with a t1/2 of approximately 0.8–1.1
days, whereas productively infected macrophages maintain viability and virus production
for at least 30 days. The latter study represents an in vitro assay and, although studies
observing the t1/2 of HIV-1 infected macrophages in vivo are lacking, existing studies
define a distinct advantage for macrophages when observing their life span and virus
production over time. Viral dynamics in vivo indicate that CCR5-using viruses
predominate early during infection. As macrophages display high CCR5 expression
levels, they represent an early target for the establishment of both chronic and latent
infection. Macrophages interact with lymphocytes during antigen presentation, conferring
direct infection to new CD4+ T lymphocytic targets. Macrophages have also been
implicated as the causative agent in central nervous system (CNS) infection of HIV-1,
which often manifests itself as HIV-associated dementia during the later stages in the
progression to AIDS [9, 10].
Macrophages represent a crucial target for establishment and maintenance of
chronic and latent HIV-1 infection. Various macrophage-like cells, including dendritic
cells, alveolar macrophages, monocyte precursors and microglial cells, contribute to the
complex interplay between systemic infection and administration of ART. Macrophages
are found in every organ system and tissue, and, because of high CCR5 expression,
represent a target for early establishment and maintenance of latent viral reservoirs.

1.3. Traditional antiretroviral therapies
The introduction of highly active antiretroviral therapy started from 1996, which has
been a great medical success in terms of increasing survival and improving the quality of
life of the HIV-infected patient population. Due to the steady advancements in HIV
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research and drug discovery, HIV infected patients on current combination antiretroviral
therapy (cART) can effectively maintain undetectable plasma virus levels for years. As
the threat of HIV/AIDS persists to rise, effective drug treatments are required to treat the
infected people. Antiretroviral therapy has markedly reduced HIV/AIDS related deaths
and opportunistic infectious diseases. This has resulted in prolonged survival of
individuals infected with HIV. Long-term medical care has significantly improved the
patients’ life expectancy and quality by suppression of plasma viral replication. Viral
resistance to antiretroviral (ARV) drugs can be addressed with two or more drug
combinations that target two to more drug targets within the same or different viral
proteins. The drugs available for the treatment of HIV/AIDS are proven to be selective
and effective with an acceptable safety to suppress plasma viral propagation. Alternate
drug combinations will be utilized if drug resistant virus appears in clinics.
As the mechanisms and proteins essential for HIV replication are characterized,
most of these viral proteins have been used as drug targets for inhibiting HIV replication.
Potent inhibitors of viral entry, replications, intergration and maturation have been
developed as therapeutic agents. These drugs are generally referred to as entry
(CCR5/CD4), reverse transcriptase, integrase and protease inhibitors, respectively.
Reverse transcriptase inhibitors have been elucidated in detail, which revealed two
distinct classes of molecules that inhibit enzyme activity through unique mechanism. In
combination, these reverse transcriptase inhibitors greatly reduce the risk of inducing
drug-resistant virus. Nowadays, there are 26 or more drugs available for the treatment of
HIV in the USA. Since single agent ART is no longer clinically relevant, the clinical use of
combinations of drugs is more efficacious compared with HIV monotherapy. Clinically,
therapeutic regimens often target multiple checkpoints in viral replication such as the
combination of protease inhibitors with reverse transcriptase inhibitors. The development
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of these agents for cART has been effective at suppressing plasma viral load and
preventing drug resistance [11].
The efficacy of ART cellular pharmacology in macrophages has significant
implications in disease progression. The interplay between ART cellular pharmacology in
macrophages directly affects viral loads, selection of resistance mutations both within
and between subsets of HIV-1 target cells, eradication of systemic virus and long-term
patient survival. Eradication of systemic HIV-1 infection is not possible without clearance
of latently infected cells. As macrophages are a sentinel target for HIV-1 infection and
latency, understanding the cellular pharmacology of current antiretroviral therapy in
macrophages is essential.
1.3.1. Entry inhibitors
Entry inhibitors inhibit entry of HIV-1 into host cells and there are two anti-HIV
drugs approved by the US Federal Drug Administration (FDA): enfuvirtide and
maraviroc. Enfuvirtide is a peptide derived from a repeat sequence of the
transmembrane portion of HIV-1 envelope, gp41, and inhibits the hairpin formation
necessary for virus-host cell fusion to occur. Enfuvirtide sensitivity was largely
independent of the coreceptor usage, and its overall antiviral activity in macrophages
correlated more closely with HIV-1 entry by CCR5 rather than with entry through
CXCR4. It is demonstrated the downstream effects of enfuvirtide relative to CXCR4versus CCR5-mediated signaling and provide a foundation for understanding the effect
of entry inhibitors on multiple cellular events in macrophages. Maraviroc is a small
molecule, which inhibits viral entry by binding to the CCR5 coreceptor and inhibiting the
receptor-coreceptor viral entry interaction required for HIV-1 entry into the host cell. The
median effective concentration (EC50) for maraviroc in primary macrophages is reported
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to be 0.5 nM for a subtype B M-R5 virus versus 0.2–2.9 nM in activated lymphocytes for
R5-using viruses across multiple subtypes [12-14].
1.3.2. Nucleoside reverse transcriptase inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs) have a well-established
regulatory pathway and distinct clinical advantages. They are low plasma protein
binding, sustained antiviral response and relative ease of chemical manufacture. There
are about eight FDA approved NRTIs: zidovudine, didanosine, zalcitabine, stavudine,
abacavir sulfate, lamivudine, entricitabine, and tonofovir disoproxil fumarate. The target
of NRTIs in HIV-1 infection is the reversed transcriptase (RT), which is active early in the
viral replication cycle. RT converts the genetic information of the virus stored at RNA into
DNA by reverse transcription, which is a process necessary for continued viral
replication. NRTIs are chiral small molecules that mimic natural nucleotides and require
intracellular phosphyorylation to become functionally active against HIV-1 RT. In the
triphosphate form, NRTIs compete with one of the four naturally occurring dNTP,
namely, dCTP, dTTP, dATP or dGTP, for binding and DNA chain elongation near the
active site of HIV-1 RT. As most NRTIs lack a 3′-hydroxyl terminus, incorporation of the
analogue into the growing DNA strand results in termination of the DNA strand and the
next phosphodiester bond is not formed. Because of these factors, both the
concentration of cellular triphosphorylated drug and the levels of cellular dNTP pools
play a key role in the efficacy of the NRTIs. Macrophages primarily remain in a resting
G1 state and undergo limited DNA synthesis. Cellular dNTP levels are significantly lower
in macrophages compared with activated cells. The EC50 for NRTIs ranges from 3 to
300 nM in macrophages for acute infection. By contrast, the EC50 is larger than 25 µM
in chronically infected macrophages. The differences indicate that chronic HIV-1
infection alters the cellular milieu in a manner that modulates the ability of NRTI to
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successfully become functionally active or subsequently inhibit viral reverse transcription
[15, 16].
1.3.3. Non-nucleoside reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) make antiretroviral
efficacy through interaction with binding pockets of HIV-1 RT and inhibiting its enzymatic
activity by causing conformational changes at or near the active site. NNRTIs approved
by FDA include etravirine, delavirdine, efavirenz and nevirapine. Although the cellular
dNTP pool does not directly affect the mechanism of action of NNRTIs, the EC50 differs
significantly for NNRTI against acute versus chronic infection in macrophages. The
EC50 for inhibition of acute HIV-1 infection in macrophages ranges from 10 to 50 nM
depending on the NNRTI; however, NNRTIs are not effective at inhibiting HIV-1
replication in chronically infected macrophages. To date, the mechanism responsible for
ineffective inhibition of viral replication in macrophages by NNRTI is incompletely
understood. If this mechanism were solely responsible for differential activity of NNRTI in
chronically activated macrophages, significant antiviral activity would probably still be
observed because establishment of new infection and subsequent p24 production would
be terminated. Intracellular accumulation of NNRTI within macrophages might present
with a significantly diminished intracellular bioavailability profile relative to lymphocytes,
which could present a direct link between differential activities of NNRTI in macrophages
versus lymphocytes [17].
1.3.4. Protease inhibitors
The HIV-1 protease is a member of the aspartic acid protease family and is
structurally related to host aspartic acid proteases including renin, cathepsin D, gastrin,
and pepsin. HIV-1 protease is a homodimer, composed of two noncovalently associated,
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structurally identical polyprotein chains. The HIV genome is composed of three major
genes including gag, pol and env. Transcription and translation of the gag and pol
regions of the virus genome resultin the production of two large precursor polyproteins,
p55 (gag) and a ribosomal frameshift product p160 (gag-pol). The enzyme active site
contains well-defined subsites in which inhibitor or substrate side chains participate in
tight binding interactions. HIV protease-mediated processing of the precursor
polyproteins p55 and p160 occurs at different cleavage sites. Phe-Pro, Phe-Leu, and
Phe-Thr are some of the scissile bonds, which can be used in the design of protease
inhibitors. Protease inhibitors (PIs) have the ability to inhibit HIV-1 replication through
competition for binding in the active site with the natural substrate. PIs can effectively
inactivate the enzyme since it is not easily cleaved. Protease inhibitors are peptide-like
chemicals that competitively inhibit the action of the virus aspatyl protease. They can
affect the proteolytic cleavage of the polypeptide precursors into mature enzymes and
structural proteins catalyzed by HIV protease. They can prevent proteolytic cleavage of
HIV Gag and Pol polyproteins that include essential structural and enzymatic
components of the virus, which prevents the conversion of HIV particles into their mature
infectious form [18].
The widely used PIs with FDA approval are amprenavir, tipranavir, indinavir,
saquinavir, lopinavir, ritonavir, darunavir, atazanavir, and nelfinavir. PIs display potent
activity in both acutely and chronically infected macrophages. The EC50 in acutely
infected macrophages ranged from 10 to 120 nM, whereas the EC50 in chronically
infected macrophages ranged from 400 to 3.3×103 nM. Higher rates of viral RNA
metabolism in macrophages is considered as a mechanism responsible for higher EC50
in macrophages. Plasma pharmacokinetics in vivo demonstrate inhibitory quotient
values that are similar to the EC50 of PI in vitro for inhibition of chronic HIV-1 infection in
macrophages. Macrophages are unique because they can be found in every tissue
12

compartment and organ systemically. Therefore, it is reasonable to suggest that many
macrophages in vivo might be exposed to significantly lower levels of drug than those
observed at inhibitory quotients in plasma in the circulating periphery [19].
1.3.5. Integrase inhibitors
Integrase inhibitors act to inhibit integration of HIV-1 proviral genome into host cell
DNA. HIV-1 integrase presents a highly selective target for anti-HIV therapeutics.
Raltegravir is a novel representative integrase inhibitor approved by FDA. Raltegravir
targets integrase, an HIV enzyme that integrates the viral genetic material into human
chromosomes, a critical step in the pathogenesis of HIV and is metabolized away via
glucuronidation, which has exhibited potent and durable antiretroviral activity [20].
1.3.6. Other potential therapeutics
The elimination of virus cannot occur by a single mechanism, thus many new
targets, including small interfering RNAs (siRNAs), carbohydrate-binding agents (CBAs),
PI3K/Akt pathway inhibitors, and immunotoxins, are explored. The siRNAs could be
useful for the induction of potent gene silencing by degradation of cognate RNA. The
use of siRNA for HIV-1 infection presents a unique challenge because systemic or
directed silencing of CXCR4 co-receptor would result in mortality, and silencing of CCR5
co-receptor could represent a selective pressure for emergence of highly pathogenic
CXCR4-using virus. CBAs target the heavily glycosylated HIV-1 envelope, impairing the
ability of macrophages or dendritic cells to recognize and perform antigen presentation
to CD4+ T-lymphocytes, subsequently impairing transfer infection. The mechanism of
CBAs is predominantly extracellular, which makes them efficacious when coadministered with other classes of drugs. The PI3K/Akt pathway is a cell survival
pathway that is activated upon apoptotic stress and functions to activate downstream
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modulators of cell survival. PI3K/Akt inhibitors were demonstrated to inhibit HIV-1
replication in acutely infected primary macrophages, and their antiviral activity was only
observed when drugs were co-administered with a compound that positively modulates
nitric oxide-induced cytotoxicity in HIV-1 infection. Immunotoxins might provide a
mechanism for targeted elimination of HIV-1-infected cells, and both novel design of
immunotoxin-based antiviral agents and their effect on macrophages remains an
ongoing area of research. Inhibitors targeting HIV-1 accessory proteins provide a
targeted approach for elimination of HIV-1 within infected cells. Vpu provides an
attractive target because interference with Vpu acts post-integration to confer abnormal
packaging of newly formed virions [21].
Even though combination antiretroviral therapy (cART) provides stable viral
suppression, it is still not perfect due to the undesirable side effects, especially for
people undergoing long-term treatment. Besides, the traditional therapies find their
limitations in multidrug resistance, lack of viral replication-targeted therapy. Traditional
therapy is not able to eradicate HIV from infected individuals. During the early stages of
HIV infection, HIV establishes reservoirs within cells where HIV lies latent, and tissues,
which are inaccessible to optimal levels of antiviral drugs, thus escaping the action of
antiretroviral drugs. Therefore, eliminating or preventing viral infection in macrophages is
a key element to achieve viral eradication, and new strategies to enhance penetration of
antiviral therapeutics in macrophages are urgently needed. Eradication of systemic HIV1 infection is not possible without clearance of latently infected cells. For these reasons,
understanding dynamics of ART pharmacology in macrophages and subsequently
eliminating productive infection in these cells, is critical to eliminating systemic HIV-1
infection.
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1.4. Novel nanomedicine for antiretroviral therapy
Nanomedicine is one promising approach to target HIV in virus reservoir sites. Due
to the introduction of highly active antiretroviral therapy (HAART) as well as the impact of
preventive measures, the prevalence and incidence of HIV have declined globally over
the last decade except for parts of Eastern Europe and Central Asia where a slight
increase has been observed.

However, although potent compounds have been

developed to suppress virus replication into undetectable levels in the blood of HIV
infected patients, it is still a challenge to completely cure patients from HIV/AIDS.
Therefore, there is an urgent need to investigate the residual viral source, virologic and
physiologic mechanisms that allow viral persistence, in order to develop targeted drug
delivery strategies to eliminate residual virus in HIV infected patients.
To realize long-acting therapy, sustained dosage forms have had an extensive
history and proven record of contribution to improve patient compliance. Formulation
research and investigation has become indispensable in improving patients’ life quality.
For chronic treatments, converting multiple daily doses to once-a-day dosing with
sustained release dosage form has shown light to enhance patient compliance. The
application of nanoformulations has been proven to be an important area of
pharmaceutical research and development.
Nanoparticles or nanomedicine refer to drug carrier particles and complexes in the
range of 10-1000 nm. Nanoformulations include nanocrystals, colloids, nanoparticles,
lipid vesicles, liposomes, biopolymers, and protein aggregates. These nanoformulations
are intended to improve pharmaceutical properties and drug response by improving drug
solubility, stability, biodistribution, pharmacokinetics, safety and efficacy.
Nanotechnology-based drug delivery systems could potentially enhance cellular
uptake of antiretroviral drugs into HIV host and infected cells in vitro and improve the
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pharmacokinetics, pharmacodynamics and biodistribution of ARV agents in various
rodent models. It should be noted that most of these reports are in early stage and use
only a single agent formulation, which is no longer acceptable clinical practice for HIV
therapy. The potential of nanotechonology to modify tissue distribution and extend
plasma half-life of HIV drugs was demonstrated. When the antiretroviral drug is
encapsulated into a nanosystem, its absorption, metabolism and excretion is not
exclusively governed by drug properties; rather, the nanosystem’s physical-chemical
properties, particularly surface-exposed molecules and electric charge, and size could
modify the sustaining time and metabolic and elimination rates. Most current
nanomedicine platforms for HIV treatment focus on drug delivery in the blood and on
improving pharmacokinetic profiles. To reduce off-target effects and improve on-target
drug distribution into tissues and cells that mediate or are linked to a clinical syndrome,
an innovative nanoformulation must be stable both in vitro and in vivo for sufficient
duration and exhibit physiochemical properties that allow distribution and localization of
drug particles within the sites of interest, while minimizing peripheral toxicities [22, 23].
1.4.1. Polymeric nanoparticles
Polymeric nanoparticles have shown great potentials in HIV therapy since
polymers are versatile and can be customized to allow for encapsulation and controlled
release of therapeutic agents from the nanoparticles. They can also realize reservoir
targeting through decoration with ligands that bind to receptors on the target site.
Peptides, proteins and antibodies are most widely used targeting ligands, which have
shown to promote binding and uptake of nanoparticles encapsulating the drugs.
Biodegradable

polymers,

polymethylmethacrylate

like

(PMMA),

polyethylene
and

glycol-block-polylactide

(PEG-PLA),

methylmethacrylate-sulfopropylmethacrylate

(MMA-SPM), have been applied to encapsulate antiretroviral drugs. Polymeric
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nanoparticle with small particle sizes were found to improve drug loading efficiency and
uptake. Modification of the polymers with ligands that target receptors expressed at the
surface of endothelial cells has greatly improved antiretroviral efficacy. This delivery
system can also enhance drug encapsulation and subsequent intracellular delivery in
macrophages [22, 23].
1.4.2. Micelles
Micelles are self-assembled colloidal systems consisting of amphiphilic molecules
that spontaneously aggregate into particles at a concentration beyond the critical micelle
concentration (CMC). A typical micelle has hydrophilic heads forming a shell structure,
and the inner core structure serves as a reservoir for poorly water-soluble drugs. They
have advantages including relatively small sizes (10-100 nm), ease of preparation, and
prolonged in vivo circulation, which enable them to cross all kinds of physiological
barriers. The application of Pluronic® copolymers inhibits efflux trasnporters, like Pglycoprotein (Pgp) and Multidrug Resistance Protein (MRP), consequently facilitate drug
delivery of substrates. Pluronic® block copolymers contains one hydrophobic
poly(propylene oxide) (PPO) as the core, and two hydrophilic poly(ethylene oxide) (PEO)
termini. Using polarized monolayers of bovine endothelial cells, Batrakova et al.
examined the influence of Pluronic® block copolymers on the permeability of drugs,
including Pgp substrates, organic anion transporter substrates, and compounds with less
specificity for efflux transporters. The results indicated a 1.3- to 20-fold enhancement in
the permeability of all the compounds evaluated. It is also demonstrated Pluronic® P85
could enhance drug tissue drug permeability and facilitate antiretroviral efficacy in a
severe combined immunodeficientcy (SCID) mouse model of viral encephalitis [24-26].
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1.4.3. Liposomes
Liposomes are artificially constructed vesicles that consist of an aqueous core
separated from the continuous aqueous solvent by one or more spherical, bilayer
membranes of surfactant molecules. Liposomes are composed of phospholipids, and
may contain small amounts of other molecules that serve as cellular recognition markers
and cholesterol that regulates membrane fluidity and stability. As drug delivery systems,
liposomes have the capability of encapsulating both hydrophobic as well as hydrophilic
payloads. Liposomes have several other benefits, such as solubilization improvement,
protection of cargoes from enzymatic degradation and enhancement of intracellular
uptake. Liposomes have been used to deliver antiretroviral agents to cross tissue
barriers through receptor-mediated transcytosis. Besides, cell-penetrating peptides
(CPP) and antibody conjugation are alternative approaches for liposomes to penetrate
HIV reservoir. Mononuclear phagocytic system is another liposomal delivery mechanism,
which can significantly increase the drug half-life in the central nervous system (CNS).
Surface-engineered liposomes have been developed to target the lymphoid virus
reservoir by incorporating surface charge or site-specific targeting ligands. Liposomes
with negative surface charge have shown higher accumulation in lymph nodes and
spleen compared to particles with positive charge [27].
1.4.4. Nanosuspensions
Nanoformulated antiretroviral therapeutics (nanoART) was developed in our
laboratory in the past decade.

NanoART are polymer excipient coated drug

nanosuspensions, which demonstrate high drug loading capacity, controllable size and
charge, and tunable surface conjugation. Antiretroviral drugs could be formulated
through high-pressure homogenization and wet milling for long-acting antiretroviral
therapy. Mononuclear phagocyte targeted nanoART for delivery to HIV reservoirs was
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developed with high drug loading, improved cell uptake and sustained drug retention.
Drugs can be delivered into the target sites at levels above the effective therapeutic
concentrations through mononuclear phagocytes. To improve pharmacokinetics and
pharmacodynamics (PK/PD) of antiretroviral therapy, we further developed nanoART
targeted to HIV reservoirs. Previous studies have shown that folate receptor (FOLR) is
overexpressed on activated macrophages. Based on these findings, folate-decorated
drug delivery systems have been developed to target macrophages for the treatment of
inflammatory diseases with improved therapeutic efficacy. Folic acid was conjugated
onto the coating excipient poloxamer 407 (P407) to generate folate-decorated nanoART
for macrophage targeting. In vitro studies using a human MDM system, FA-nanoART
showed a 2-fold increase in drug uptake, longer drug retention, and superior
antiretroviral efficacy over non-targeted nanoART. In vivo PK/PD studies showed that
FA-nanoART increased the plasma levels of ATV approximately 5-fold over that
observed with non-targeted nanoART [28, 29].
1.4.5. Solid lipid nanoparticles
Solid lipid nanoparticles (SLNs) usually comprise biocompatible lipids, that are
solid at room temperature or surfactants for emulsification. They are typically solid
particles consisting of one or more biocompatible solid lipids, which are stabilized by
emulsifiers. The particle size ranges from approximately 50 to 1000 nm. They possess
advantages like long retention, superior biocompatibility and biodegradability, excellent
stability and loading capability as well as ease of introduction of targeting ligands. SLNs
for CNS delivery of ART were developed, and the permeability of stavudine, delavirdine,
and saquinavir encapsulated in different nanocarriers, including polymer nanoparticles
and SLN, were tested across an artificial BBB. There was increased permeability of SLN
encapsulated drugs compared to free drugs. In addition, delavirdine and saquinavir
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loaded SLN showed better permeability than those loaded into polymer nanoparticles
[30].
1.4.6. Dendrimers
Dendrimers are a highly branched complex multiple repeating structures of a
monomer. They are comprised of hydrophobic cores and highly branched surface
functional groups that make them ideal for transport of drugs across biological barriers.
The end groups of these molecules can be functionalized to generate dendrimers that
can be used as drug carriers and targeting moieties can be attached that influence
biodistribution and toxicity of the dendrimers. Poly(amido amide) (PAMAM), the most
commonly used dendrimer has been shown to incorporate several anticancer drugs.
However, no dendrimer-based delivery systems have been approved for anti-HIV
treatment due to their high cellular toxicity [31].
1.4.7 Nanomedicine in antiretroviral therapy
Significant progress has been made to treat HIV/AIDS to improve the life quality of
HIV infected people in the last decades. The utilization of nanomedicine in ART has
successfully shifted rapidly progressive HIV infection to a disease with little detectable
viral load in patients. It is still a big challenge so far to eradicate HIV due to the
occurrence of drug resistance and viral reservoirs. Nanotechnology-based drug delivery
systems can improve antiretroviral therapy by more precisely controlling drug
concentrations in target cells and tissues, thus enhance uptake of antiretroviral agents
into HIV-infected cell and tissue reservoirs and improve the pharmacokinetics,
pharmacodynamics and biodistribution of antiretroviral agents using targeting ligands
and improving drug delivery across tissue barriers. The goal of HIV eradication can be
achieved through developing different nanomedicine platforms and decorating
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nanomedicines with specific ligands to interact with receptors expressed on HIV infected
cells.
Nanomedicine has provided new tools and rationales in the development for novel
strategies for HIV/AIDS treatment. The rational design has provided new candidates
against HIV with improved solubility, stability and pharmacokinetic and adherence
properties. Most current nanomedicine platforms focus on drug delivery in the blood and
on improving pharmacokinetic profiles. Nanosustained drug release formulations could
maintain plasma drug concentrations for weeks and even months. Although there are
benefits and advantages of applying the systems approach to novel nanoformulations,
there are still challenges that need to be overcome in the future to translate academic
research into the clinical setting. These include the biocompatibility of excipients, safety,
stability and the scale-up procedure for large-scale preparations. Nanomedicine
platforms should be explored to develop combination therapies for safe and effective
long-acting HIV therapy to improve patient compliance and life quality.

1.5. Hypothesis and goals
This study focuses on developing long-acting antiretroviral prodrug with enhanced
hydrophobicity and stability. A hydrophobic lamivudine (3TC) prodrug is successfully
synthesized

and

incorporated

into

targeted

and

non-targeted

nanocrystalline

formulations to improve drug half-life, enhance macrophage uptake, and sustain
antiretroviral efficacy. Folic acid targeted parenteral nanoformulations are prepared for
improved pharmacokinetics and improved antiretroviral therapy. This long-acting
antiretroviral drug delivery system can serve both as drug transporters and as facilitators
of viral clearance. Macrophage loading capacities and intracellular compartments of
nanoparticle depots are studied. Macrophage endosomal compartments can be
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harnessed for particle storage, release and drug trafficking. NanoART is expected to
provide increased drug uptake, retention in macrophages, which facilitates its long acting
antiretroviral efficacy. Macrophage can act as drug transporters for improved clinical
stability and bioavailability. Regulation of phagolysosomal endocytic pathway is also
studied. The co-localization of nanoformulated atazanavir (ATV) at endosomal sites of
viral assembly is expected to affect regulatory proteins and pathways that contribute to
viral clearance. The cell targeted small magnetite ART (SMART) particles is developed
to facilitate drug adherence and improve disease outcomes. Rapid noninvasive
determination of drug biodistribution in virus-target tissues and reservoirs for nanoART
can realize noninvasive assessments of antiretroviral drug tissue distribution through
magnetic resonance imaging (MRI) techniques.

Chapter II.
22

Long-acting lamvudine prodrug
design and formulation
development
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2.1. Abstract
The next generation of antiretroviral medicines will be characterized by infrequent
parenteral administration, maintenance of continuous drug concentrations and viral
reservoir-targeted drugs. This will enable reductions in toxicities, viral loads and
resistance patterns while improving drug regimen adherence. Perhaps most
importantly such advances would facilitate viral clearance in infectious reservoirs that
include gut-associated lymphoid tissue, lymphoid nodes, the genitourinary system and
the central nervous system.

While such progress has been now realized for

hydrophobic integrase and select nonnucleoside reverse transcriptase inhibitors, very
limited success has been achieved with the more hydrophilic short-acting nucleosides.
To overcome such limitations, we developed a two-step synthesis to create a longacting lamivudine (2’,3’-dideoxy-3’-thiacytidine, 3TC). A stable hydrophobic pro-drug
crystal formulation was produced by poloxamer drug encasement. Conversion of the
formerly hydrophilic 3TC significantly extended its bioavailability facilitated by chemical
drug conjugation to a fatty acid and creating a myristoylated drug. A folate targeted
poloxamer 407 coated a newly formed nanocrystalline pro-drug markedly improving
cell uptake, bioavailability and pharmacokinetic profiles. Reduced cytotoxicity and
robust antiretroviral activities were also observed. These findings bring the idea of
long-acting antiretroviral medicines closer to the mainstay of clinical availability.

2.2. Introduction
The introduction of nanomedicine in antiretroviral therapeutic regimens has
impacted the treatment of HIV infection. Long-acting nanoformulated antiretroviral
therapy (nanoART) has the real potential to improve patient adherence, decrease
systemic toxicities, and sustain viral suppression [32-37]. However, the remaining
24

challenge to bring nanoART to the forefront of antiretroviral therapy is to
nanoformulate a broad range of hydrophilic drugs. While hydrophilic drugs are widely
used in the clinic, their drawbacks include the need for frequent administration by rapid
clearance, low intracellular absorption and suboptimal biodistribution.

Cellular and

tissue toxicities also reduce their clinical effectiveness. Ideal drug delivery systems and
encapsulation strategies specifically for hydrophilic antiretroviral nucleoside reverse
transcriptase inhibitors (NRTIs) are still under investigation.
NRTIs are the backbone of combination antiretroviral therapy in the treatment of
HIV infection [38-40]. Lamivudine (3TC) by competing with an endogenous nucleotide
transcriptase enzyme leads to viral DNA chain termination that follows incorporation of
the active 3TC phosphorylated anabolite in place of endogenous cytidine triphosphate
during reverse transcription. 3TC has potent antiviral effects on HIV-1, HIV-2, and
hepatitis B virus [41-44]. However, the drug is < 36% protein bound and with a half-life
of 5-7 hours and rapid renal elimination by tubular secretion is catalogued as a shortacting drug. These characteristics minimize its utility as a once daily fixed dose
medicine.
Myristoyltransferase (NMT) effects myristoylation of proteins during the HIV life
cycle [45-47]. Fatty acid analogues of myristic acid can inhibit NMT and can be used to
convert a hydrophilic 3TC into a hydrophobic drug [48-50]. Myristolic 3TC (MTC) was
encased into a nanoparticle with poloxamer 407 with well-distributed size and stable
physical properties. Folic acid, the ligand for the folate receptor expressed on
macrophages, attached to drug nanoparticles can facilitate drug uptake [51, 52].
Moreover, for nanoART macrophage uptake, the targeting ligand folic acid can
facilitate drug uptake and retention in monocyte-macrophages [53]. We developed
targeted MTC nanoformulations using folate as a targeting ligand, enabling it to affect
cellular uptake, antiretroviral efficacy, and antiretroviral pharmacokinetic behavior. The
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idea of formulating 3TC prodrug to improve therapeutic outcomes for patients receiving
long-term antiretroviral treatment is novel and of significant potential utility.

2.3. Materials and methods
2.3.1. Reagents and antibodies.
3TC was acquired from GlaxoSmithKline Inc. (Research Triangle Park, NC, USA).
Poloxamer 407 (P407) and CF488-succinimidyl ester (CF488) were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Sephadex LH-20 was obtained from GE
Healthcare (Piscataway, NJ, USA). Pooled human serum was obtained from
Innovative Biologics (Herndon, VA, USA). Macrophage colony-stimulating factor (MCSF) was prepared from 5/9m alpha3-18 cells (ATCC; CRL-10154) cultured in ATCC
complete growth medium as described previously [54]. Rabbit anti-human antibodies
to Rab5, Rab7, Rab11, and Rab14 and Alexa Fluor 568 goat anti-rabbit IgG were
purchased from Santa Cruz Biotechnology (Dallas, TX, USA). TRIzol reagent was
obtained from Invitrogen (Grand Island, NY, USA).
2.3.2. Synthesis of hydrophobic 3TC derivative.
The hydrophobic 3TC derivative (MTC) was synthesized according to the scheme
shown in Figure 2.1A. Briefly, 3TC (4 mmol) was dissolved in dimethylformamide
(DMF, 6 mL) in an ice bath, imidazole (6 mmol) and tert-butyldimethylsilyl chloride (4.8
mmol) were added separately and the reaction mixture was stirred at room
temperature (25 °C) overnight. After the completion of reaction, the reaction mixture
was concentrated at reduced pressure and purified with silica gel column
chromatography using dichloromethane and methanol (2-10%) as eluents. The yield
compound was dissolved in dry pyridine (6 mL). A solution of 4,4’-dimethoxytrityl
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chloride (DMTr-Cl, 8 mmol) was added to the reaction mixture dropwise at 0 °C. The
temperature was raised to room temperature, and stirring was continued overnight.
The reaction mixture was neutralized with saturated sodium bicarbonate solution (200
mL) and extracted with dichloromethane (200 mL) for three times. The organic layer
was separated and concentrated in vacuo. The residue was purified with silica gel
column chromatography using dichloromethane and methanol (2-10%) as eluents. The
yield

compound

was

dissolved

in

tetrahydrofuran

(THF,

6

mL)

and

tetrabutylammonium fluoride (6.2 mL, 1.5 molar ratio) was added dropwise and stirred
for 4 h. The reaction mixture was concentrated at reduced pressure, and the residue
was purified with silica gel column chromatography using dichloromethane and
methanol (2-10%) as eluents. The yield compound was dissolved in DMF (10 mL).
Then myristic acid acid (945 mg, 2 molar ratio), 1-[Bis(dimethylamino)methylene]-1H1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU, 1.72 g, 2.2 molar
ratio) and N,N-diisopropylethylamine (DIEA, 1.5 mL, 3.4 molar ratio) were added to the
mixture separately. The reaction mixture was concentrated at reduced pressure, and
the residue was purified with silica gel column chromatography using dichloromethane
with 2% methanol as eluents. Acetic acid (10 mL) was added to the yield compound
and the reaction mixture was heated at 80 °C for 30 min. The reaction mixture was
concentrated at reduced pressure, and the residue was purified with silica gel column
chromatography using dichloromethane with 2% methanol as eluents. The chemical
structure of final product was characterized by nuclear magnetic resonance
spectrometry (1H NMR) determined on a Varian Unity/Inova-500 NB (500 MHz; Varian
Medical Systems Inc., Palo Alto, CA, USA). Chemical shifts are reported in parts per
million (ppm). The structure of the final compound was analyzed by FTIR spectroscopy
using a Spectrum Two FT-IR spectrometer,(PerkinElmer, Waltham, MA, USA) .
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2.3.3. NanoMTC manufacture and characterization.
MTC nanoparticles were formulated by high-pressure homogenization (Avestin
EmulsiFlex-C3; Avestin Inc., Ottawa, ON, Canada), using P407 and FA-P407 to
encase the drug crystals. For the non-targeted MTC formulation (called NMTC), the
suspension contained modified 3TC (1% [wt/vol]) and P407 (0.5% [wt/vol]) and for the
targeted MTC formulation (called FA-NMTC), the suspension contained modified 3TC
(1% [wt/vol]), P407 (0.3% [wt/vol]) and FA-P407 (0.2% [wt/vol]). The suspension was
premixed overnight in 10mM HEPES buffer at room temperature and then
homogenized at 20,000 PSI for about 360 passes until the desired particle size of
about 350 nm was achieved. The size, zeta potential, and polydispersity (PDI) were
determined by dynamic light scattering (DLS), using a Malvern Zetasizer Nano Series
Nano-ZS (Malvern Instruments, Westborough, MA, USA). A minimum of 3 iterations
were taken, which varied by < 2%. After reaching the desired size (around 300 nm),
the sample was purified by centrifugation at 100 × g for 5 min to remove aggregated
particles and then at 20,000 × g for 30 min to collect a purified particle pellet. The
resulting particles were resuspended in 10 mM HEPES for further studies [55, 56].
2.3.4. Preparation of dye-labeled nanoMTC.
For preparation of CF488-labeled nanoMTC, CF488-P407 and P407 were
dissolved in methanol at a weight ratio of 1:4. The solvent was evaporated, and the
mixture was resuspended with 10 mM HEPES to yield a 0.5% surfactant solution.
Modified 3TC was added at a 1% weight ratio. The suspension was premixed
overnight in a light-protected environment at room temperature. The suspension was
homogenized by high-pressure homogenization and purified by centrifugation as
described above.
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2.3.5. Human monocyte isolation and cultivation.
Human monocytes were obtained by leukapheresis from HIV-1-, HIV-2-, and
hepatitis B-seronegative donors and then purified by countercurrent centrifugal
elutriation. Cells were obtained following informed consent using a protocol approved
by the University of Nebraska Medical Center Institutional Review Board. The
recovered monocytes, >98% pure by Wright-stained cytosmears, were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) with 10% heat-inactivated pooled
human serum, 1% glutamine, 50 µg/mL gentamicin, 10 µg/mL ciprofloxacin, and 1,000
U/mL recombinant human macrophage colony stimulating factor for 7 days, facilitating
cell differentiation into macrophages (MDM) [57].
2.3.6. Nanoformulated MTC particle stability.
Formulated NMTC and FA-NMTC particles were dispersed in phosphate buffered
saline (PBS) and placed into a 10 kDa dialysis tube in 2 L of PBS under stirring at
37°C. At 30 min and 1, 2, 3, 4, 6, 8 and 10 days, 100 µL of the suspension was
collected. The supernatant was dissolved in 900 µL methanol [58]. The amount of
MTC was measured by high-performance liquid chromatography (HPLC). HPLC
analysis was as previously described [59]. Triplicate 20-µL samples were assessed by
HPLC using a Synergi 4 µm Hydro-RP 80A C18 column (Phenomenex Inc., Torrance,
CA). The mobile phase, consisting of 80% acetonitrile-20% 5 mM Na2HPO4, pH 9.0,
was pumped at 1.0 mL/min with UV-visible (Vis) detection at 272 nm. MTC
concentration was determined by peak area comparison to those of a standard curve
generated with free MTC (0.049 to 50 µg/mL) [60].
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2.3.7. Cytotoxicity studies.
Cytotoxicity of native drug, modified drugs and the different nanoformulations was
evaluated by Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies Inc,
Rockville, MD, USA) [61]. Briefly, human monocytes were cultivated in a 96-well-plate
at the density of 100,000 cells per well. After 7 days of differentiation, MDM were
treated with native 3TC, MTC, NMTC, or FA-NMTC at a series of concentrations: 0.10,
0.33, 1.0, 3.3, 10.0, 33.3, and 100 mM. Four hours after treatment, 10 µL of CCK-8
was added to each well. The plate was incubated in a 5% CO2 incubator for 2 h after
which the absorbance was measured at 450 nm using a microplate reader. The cell
survival rate was calculated based on the equation below:

𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑟𝑎𝑡𝑒 % =

𝐴𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏
× 100
𝐴𝑐 − 𝐴𝑏

𝐴𝑠𝑎𝑚𝑝𝑙𝑒: 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒, 𝐴𝑏: 𝑏𝑙𝑎𝑛𝑘, 𝐴𝑐: 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
2.3.8. Nanoformulated MTC particle cell uptake.
Human monocytes were cultivated in a 12-well-plate at the density of 1.5 million
cells per well. After 7 days of differentiation, MDM were treated with 100 µM
nanoformulated MTC. Uptake of nanoMTC was assessed without medium changes for
8 h. Adherent MDMs were collected by scraping into PBS, at 1, 2, 4 and 8 h after
treatment. Cells were pelleted by centrifugation at 1000 × g for 8 min at 4°C. Cell
pellets were briefly sonicated in 200 µL of methanol and centrifuged at 20,000 × g for
10 min at 4°C. The MTC content in the cells was determined by HPLC.
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2.3.9. Antiretroviral activities.
Antiretroviral efficacy was determined by HIV-1 reverse transcriptase (RT) activity
[62, 63]. Briefly, MDM were treated with 100 µM native 3TC, MTC or nanoformulated
MTC for 4 h. Following treatment, cells were washed with PBS for three times and
cultivated with fresh medium. At 0, 5, 10 and 15 days after treatment, cells were
challenged with HIV-1ADA at a multiplicity of infection (MOI) of 0.1 infectious particles
per cell. Following viral infection, the cells were cultured for another 7 days with halfmedium exchanges every other day. Medium samples were collected on days 7 for
measurement of progeny virion production, as determined by RT activity. For
assessment of RT activity, 10 µL medium samples were mixed with 10 µL of a solution
containing 100 mM Tris-HCl (pH 7.9), 300 mM KCl, 100 mM dithiothreitol, 0.1% NP-40,
and water in a 96-well plate. The reaction mixture was incubated at 37°C for 15 min,
and 25 µL of a solution containing 50 mM Tris-HCl (pH 7.9), 150 mM KCl, 5 mM
dithiothreitol, 15 mM MgCl2, 0.05% NP-40, 10 µL/mL poly(A), 0.25 U/mL oligo, and 10
µCi/mL [3H]dTTP was added to each well; the plates were incubated at 37°C for 18 h.
Following incubation, 50 µL of cold 10% trichloroacetic acid was added to each well,
the wells were harvested onto glass fiber filters, and the filters were assessed for
[3H]dTTP incorporation by beta-scintillation spectroscopy using a TopCount NXT
(PerkinElmer Inc., Waltham, MA, USA).
2.3.10. Immunocytochemistry and confocal microscopy.
For immunofluorescence staining, cells were washed three times with PBS and
fixed with 4% paraformaldehyde (PFA) at room temperature for 30 min. The cells were
treated with blocking/permeabilizing solution (0.1% Triton, 5% BSA in PBS) and
quenched with 50 mM NH4Cl for 15 min. The cells were washed once with 0.1% Triton
in PBS and sequentially incubated with primary and secondary antibodies at room
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temperature. Slides were covered in ProLong Gold AntiFade reagent with DAPI (4’,6diamidino-2-phenylindole) and imaged using a 63× oil lens on an LSM 510 confocal
microscope

(Carl

Zeiss

Microimaging,

Inc.,

Dublin,

CA,

USA)

[28].

The

immunofluorescence was quantitated, and the percent overlap was determined using
ImageJ software, the JACoP plug-in for percent overlap, and Zeiss LSM 510 Image
browser AIM software version 4.2 for determining the number of pixels and the mean
intensity of each channel, as previously described [55]. The results are represented as
means ± standard errors of the mean.
2.3.11. HIV-1 p24 staining.
Cells in different treatment groups were fixed with 4% phosphate-buffered PFA for
15 min at room temperature. The fixed cells were blocked with 10% BSA in PBS
containing1%Triton X-100 for 30 min at room temperature and incubated with mouse
monoclonal antibodies to HIV-1 p24 (1:100; Dako, Carpinteria, CA, USA) for 3 h at
room temperature. Binding of HIV-1 p24 antibody was detected using a Dako
EnVision+ System, HRP-labeled polymer anti-mouse secondary antibody, and
diaminobenzidine staining. Cell nuclei were counterstained with hematoxylin for 60 s.
Images were taken using a Nikon TE300 microscope with a 40× objective [55, 64].
2.3.12. Pharmacokinetic studies.
All animal studies were conducted humanely according to a protocol for animal
experiments approved by the University of Nebraska Medical Center Institutional
Animal Care and Use Committee. Male Balb/cJ mice (Jackson Labs, Bar Harbor, ME,
USA) were maintained on a folate-deficient diet (Harlan Teklad TD.00434; Harlan
Laboratories, Inc., Indianapolis, IN, USA) beginning 2 weeks prior to drug
administration. Mice were injected with native 3TC, MTC, NMTC, FA-NMTC (50 mg/kg
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based upon 3TC) or PBS intramuscularly (IM). Plasma was collected at 8 h, 1, 3, 5, 7,
10 and 14 days after drug administration. Tissues (liver, kidney, brain, spleen, gut,
lymph node and muscle) were collected after sacrifice on day 14. 3TC and MTC from
plasma and tissues were extracted using acetonitrile and assayed by UPLC-MS/MS. In
preparation for drug analysis, 3TC and MTC were extracted from plasma (20 µL) using
1 mL of acetonitrile. Internal standard was added to each sample (10 µL) and
consisted of 1.33 µg/mL deuterated-3 isotope of lamivudine (3TC), 0.665 µg/mL
deuterated-4 isotope of ABC, and 0.5 µg/mL lopinavir. Samples were dried using a
ThermoScientific Savant Speed Vacuum (ThermoScientific, Waltham, MA, USA), and
reconstituted in 80% v/v methanol in Optima grade water. Standards were prepared
with initial 3TC concentrations (ng/ml) of: 13,300; 5,320; 2,660; 1,330; 532; 266, 133;
53.2; 26.6, 13.3; 5.32; 2.66; and 1.33 for final 3TC concentrations (ng/mL) of: 500,
200, 100, 50, 20, 10, 5, 2, 1, 0.5, 0.2, 0.1 and 0.05. MTC standards had initial
concentrations of (ng/mL): 5000, 2000, 1000, 500, 200, 100, 50, 20, 10, 5, 2, 1, and
0.5 and the same final concentrations as the 3TC standards. Plasma standards were
prepared by extracting 20 µL of blank plasma from control Balb/cJ mice
(BioreclamationIVT, Hicksville, NY, USA) into 1 mL of acetonitrile. The same internal
standard was added to each standard.
For tissue preparation, 50-100 mg of liver, spleen and lymph node were
homogenized in 4 volumes of an esterase inhibitor mixture (12.5 mg/mL sodium
fluoride and 3.75 mg/mL EDTA solution in Optima grade water) and 2.5 µL of a
protease inhibitor (10 mM PMSF in HPLC grade isopropanol). Tissue homogenate
(100 µL) was mixed with 10 µL of internal standard (5 µg/mL deuterated-3 isotope of
lamivudine (3TC), 2.5 µg/mL deuterated-4 isotope of ABC, and 2 µg/mL lopinavir) and
extracted in 300 µL methanol. Supernatant was used directly for MTC analysis or
mixed with water for 3TC analysis. Standards were prepared with initial 3TC
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concentrations (ng/mL) of: 50,000; 20,000; 10,000; 5,000; 2,000; 1,000; 500; 200; 100;
50; 20; 10; and 5 for final 3TC concentrations (ng/mL) of: 500, 200, 100, 50, 20, 10, 5,
2, 1, 0.5, 0.2, 0.1 and 0.05. MTC standards had initial concentrations of (ng/mL):
20,000, 8,000, 4,000, 2,000, 800, 400, 200, 80, 40, 20, 8, 4, and 2 and the same final
concentrations as the 3TC standards. Tissue standards were prepared by
homogenizing 50-100 mg of blank liver, spleen or lymph node from control Balb/cJ
mice in 4 volumes of the same esterase and protease inhibitor mixtures as the
samples. The same internal standard was added to each standard then extracted in
300 µL of methanol. Drug quantitation was completed using a Waters ACQUITY Hclass UPLC system (Waters, Milford, MA, USA) connected to a Waters Xevo TQSmicro mass spectrometer with an electrospray ionization (ESI) source.
Chromatographic separation of 10 µL 3TC sample injections was achieved using
an ACQUITY UPLC CSH C18 column (1.7 µm, 2.1 mm x 100 mm) using a 13 min
gradient of mobile phase A (7.5 mM ammonium bicarbonate in Optima grade water
and adjusted to pH 7 using glacial acetic acid) and mobile phase B (100% Optima
grade methanol) at a flow rate of 0.25 mL/min. Initial mobile phase conditions of 90% A
were held for 2.5 min, decreased to 5% A over 6.5 min, held at 5% A for 1.3 min, then
increased to 90% A over 0.45 min and held for 2.25 min. MTC chromatographic
separation was achieved using the same CSH column and mobile phases, but with a
16 min isocratic method using 19% mobile phase A and flow rate of 0.3 mL/min. Drug
was detected in the ESI positive mode with a cone voltage of 4 V and a collision
energy of 10 V. Multiple reaction monitoring (MRM) transitions used for 3TC and MTC
were 230.23 > 111.97 and 440.10 > 111.97 respectively. The deuterium-4 isotope of
3TC was used as the internal standard for 3TC quantitation and had an MRM
transition of 233.23 > 114.97. Lopinavir was used as the internal standard for MTC
quantitation and had an MRM transition of 629.18 > 447.20. Spectra were analyzed
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and quantified by MassLynx software version 4.1. All calculations were made using
analyte peak area to internal standard peak area ratios.
2.13. Statistics.
All the data were analyzed by one-way analysis of variance (ANOVA) and Tukey’s
multiple-comparison test using GraphPad Prism software (GraphPad Software, Inc.,
La Jolla, CA). All the cellular based experiments were replicated three times and the
animal experiment was replicated twice. The sample size was determined according to
published guidelines with a minimum of 5 animals per group (n=5). No outliers from
animal or cell experiments were excluded. Differences were considered significant at a
P value of <0.05.

2.4. Results
2.4.1. Characterization of chemically modified 3TC.
A hydrophobic 3TC derivative (MTC) was synthesized successfully, as illustrated
by the 1H NMR and FT-IR spectrum in Figure 2.1B and 1C. In the 1H NMR spectrum,
chemical shifts of 0.9 and 1.3 ppm represented the 1° (RCH3) and 2° (R2CH2) aliphatic
protons derived from the fatty acid chain. The protons connected to the ester (-H2CCOOR) contributed to the peak at 2.4 ppm. In the FT-IR spectrum, the wavenumbers
of 2917 and 2850 cm-1 were attributed to the C-H stretch, which belonged to the alkyl
derivative derived from the fatty acid chain conjugated to the native 3TC; the
wavenumber of 1692 cm-1 was attributed to the C=O stretch from the ester bond. The
solubility of the hydrophobic MTC was determined to be 100 µg/mL in water, compared
to 70 mg/mL water solubility of native 3TC.
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2.4.2. Characterization of nanoformulated MTC.
The nanoformulations were manufactured by high-pressure homogenization.
Particle size, charge and PdI for all formulations were determined by dynamic light
scattering (DLS). The schematic diagram of the targeted MTC particles was illustrated
in Figure 2.1D and the characteristics of different formulations are summarized in
Figure 2.2A. For FA-NMTC nanoparticles, a 40% FA-P407/60% P407 polymer solution
was used to formulate the MTC. Both NMTC and FA-NMTC showed equivalent
physicochemical characteristics. For NMTC nanoparticles, the particle size was 375 ±
21 nm with a PdI of 0.21; while the FA-NMTC showed a slightly larger particle size of
433 ± 23 nm with a PdI of 0.25. The zeta-potential for FA-NMTC decreased to -19.7 ±
1.3 mV compared with -21.0 ± 0.8 mV for NMTC. The changes in size and zetapotential can be attributed to the FA conjugated to the P407 polymer. High drug
loading (75.0% for NMTC, 76.9% for FA-NMTC) and encapsulation efficiency (96.3%
for NMTC, 98.4% for FA-NMTC) were found for both formulations.
2.4.3. Nanoformulated MTC particle stability.
The stability of NMTC and FA-NMTC nanoformulations is illustrated in Figure 2.2B.
There was no significant burst release in the first 8 h and sustained MTC
concentrations were seen over 12 days. The cumulative MTC release reached 70.0%
on day 3 and 94.8% on day 12 for NMTC, and 76.4% on day 3 and 96.7% on day 12
for FA-NMTC.
2.4.4. Cytotoxicity of nanoformulated MTC.
Cytotoxicity of native 3TC, MTC and both nanoformulations was evaluated by Cell
Counting Kit-8. MDM were treated with native 3TC, MTC, NMTC, or FA-NMTC at
different concentrations for 4 h and cytotoxicity is shown in Figure 2.2C. Native 3TC
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showed strong cytotoxicity when the drug concentration increased to above 1 mM and
the cell survival rate decreased to 9.6% at 3.3 mM. Compared with native 3TC, MTC
shower much lower cytotoxicity. The cell survival rate was 95.9% at 3.3 mM and
slightly decreased with the increment of drug concentration. The cytotoxicity for both
nanoformulations was between native 3TC and MTC and no significant difference was
observed between these two formulations.
2.4.5. Macrophage uptake.
MDM uptake of nanoformulated MTC was assessed and MTC levels were
quantified by HPLC. Cells were exposed to nanoMTC for 8 h at 100 µM (42.7 g/mL) for
both NMTC and FA-NMTC treatment. As shown in Figure 2.2D, the uptake of
nanoMTC was increased over the first 2 h, and maximum uptake was observed at 2 h
for both nanoformulations. At 2 h, the uptake of FA-NMTC was 24.88 µg/106 cells,
which was more than 2 times higher than that of NMTC (10.45 µg/106 cells). After 2 h,
cell drug levels began to decrease, and drug levels of MTC for NMTC and FA-NMTC
at 8 h were 2.06 and 2.85 µg/106 cells, respectively.
2.4.6. Antiretroviral activities of nanoformulated MTC.
To assess the antiretroviral activity of nanoMTC treatment HIV-1 RT activity was
determined in HIV-1-infected MDM treated with native 3TC, NMTC or FA-NMTC. Cells
were treated with 100 µM of native 3TC or nanoformulated MTC for 4 hours. At this
time the medium was removed, cells were washed 3 times with PBS and fresh
medium without drug was added prior to HIV-1ADA challenge at days 0, 5 and 10 after
treatment. Infected cells were cultured for an additional 7 days and RT activity in the
culture medium was determined. Significant differences were found between cells
treated with native 3TC or nanoformulated MTC. For native 3TC treated cells, RT
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activity was suppressed only in the day 0 infection group. After day 5, the RT activity
for the 3TC treated group increased dramatically over time, and no viral suppression
was observed at day 15. In contrast, for nanoformulation treated groups, sustained
antiretroviral activities were observed. The RT activities were suppressed to a
relatively low level (< 25%) during the first 10 days. At day 15, the RT levels for NMTC
and FA-NMTC were 59.8% and 68.5%, respectively, compared with 110.0% for the
native 3TC group. Significant differences were observed between NMTC and FANMTC during the first 10 days (p<0.05) and FA-NMTC showed greater antiretroviral
activity compared with NMTC, however, the difference was not significant at day 15
(Figure 2.3A). These results were confirmed by HIV-1 p24 staining (Figure 2.3B).
NMTC and FA-NMTC showed greater antiretroviral efficacy compared with native 3TC,
and much less p24 staining was observed in these two groups. FA-NMTC shower
greater suppression of viral replication especially in the first 10 days, little to no p24
antigen was detected in MDM treated with FA-NMTC.
2.4.7. Immunocytochemistry and confocal microscopy.
To assess subcellular behavior of the nanoformulated MTC particles, fluorescentlylabeled nanoparticles were used to visualize if co-localization of endolysosomal
proteins and nanoMTC occured. CF488-labeled nanoMTC was prepared and Rab 5, 7,
11, 14 and LAMP 1 were selected as targeted proteins. Immunostaining was
performed 4 h after particle incubation for visualization of endocytic compartments and
nanoMTC co-localization. As observed nanoMTC distributed in a punctate pattern
throughout the cytoplasm and perinuclear cell regions (Figure 2.4). NanoMTC was
found predominantly in late (Rab 7) and recycling (Rab 11 and 14) endosomes [51],
and this immunofluorescence co-localization demonstrated that nanoMTC was taken
and stored in macrophages through the endolysosomal pathways. Our previous
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studies have demonstrated that the HIV reservoir exists mainly in late and recycling
endosomes, and HIV-1 and nanoformulations deregulated cellular proteins in an
opposing manner [56], supporting the idea of subcellular-targeted nanoparticles for
long acting antiretroviral therapy.
2.4.8. Pharmacokinetics.
Balb/cJ mice were administered nanoformulated MTC at 50 mg/kg based on 3TC
concentration to determine the pharmacokinetic parameters for both NMTC and FANMTC as the scheme shown in Figure 2.5A. Plasma drug concentrations following
formulation treatment were analyzed by UPLC-MS/MS and data are presented in
Figure 2.5B and C. At each time point, very little MTC was detected, which indicated
the complete conversion of MTC to 3TC. Higher and more sustained drug levels were
observed for MTC nanoformulation treated groups and plasma drug levels were
maintained over 10 days for both nanoformulations. At day 1, no drug could be
detected in plasma from the native 3TC treated group; the drug levels for MTC, NMTC
and FA-NMTC groups were 58.65 ± 6.94, 349.25 ± 12.51, and 383.24 ± 13.77 ng/mL,
respectively. At day 3, little drug was detected in plasma from the MTC treated group,
whereas plasma drug levels for NMTC and FA-NMTC groups were 131.30 ± 18.09 and
151.63

±

23.16

ng/mL,

respectively.

Compared

with

NMTC,

FA

targeted

nanoformulation showed prolonged drug release and plasma drug levels were more
than 2 fold higher than these of NMTC from day 5 to day 14. At day 14, the plasma
drug level for FA-NMTC was 22.66 ± 12.53 ng/mL and that for NMTC was at the limit
of quantitation (< 0.5 ng/mL). Tissue drug levels are shown in Figure 2.5D; no 3TC
was detected in tissues for mice treated with native 3TC or MTC after 14 days. Drug
levels for the FA-NMTC treated group were greater than 2-fold higher than these for
the NMTC group in liver, spleen and lymph nodes.
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2.5. Discussion
Reverse-transcriptase inhibitors are a class of antiretroviral drugs used to treat
HIV/AIDS and hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA
polymerase that is required for replication of HIV and other retroviruses. Lamivudine
(3TC) is a typical nucleoside analog reverse-transcriptase inhibitor (NRTI). Its
favorable safety profile, low potential for drug interaction, good tolerability, and high
resistance barrier makes it one of the preferred choices for HIV/AIDS therapy in
multiple clinical scenarios. However, the low protein bound, short half-life and fast
clearance of 3TC limit its clinical application. In this paper, we describe development of
a nanoformulated 3TC prodrug in order to improve its clinical potential.
Myristic acid was used to synthesize the hydrophobic MTC. This 14-carbon alkyl
chain could significantly decrease the water solubility of native 3TC and improve the
drug-protein, drug-membrane interactions during systemic circulation. In the presence
of NMT, HIV-1 viral proteins are covalently attached to myristic acid, which exposes
them to the antiretroviral drug sufficiently. It has been reported that NMT is a crucial
enzyme involved in catalyzing the myristoylation of capsid protein p17, Pr160gag-pol, and
Pr55gag, which are involved in the life cycle of HIV-1 [46]. Myristic acid has been shown
to inhibit NMT [65-67]. HIV-1 replication could, consequently, be inhibited by the
myristoylated 3TC. An ester bond was formed after chemical conjugation, which did
not affect the antiretroviral efficacy of the prodrug, since the ester bond could be easily
hydrolyzed in the presence of intracellular esterases, including lysosomal acid lipase,
phospholipase, acetylhydrolase, nucleases and lipoprotein lipase, which are localized
mainly in lysosomes. These enzymes catalyze the breakdown of acyl groups and
hydrolyze compounds taken into lysosomes. In our study, the hydrophobic MTC
presumably diffused through the cell membrane into different cell compartments. The
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prodrug was transported into lysosomes, degraded by the esterases, and released the
native 3TC to provide antiretroviral activity. Interestingly, MTC particles exhibited
comparable antiretroviral efficacy to native 3TC as shown in day 0 RT result. Relatively
low RT levels were observed in cells treated with both MTC formulations, which
indicates that the myristoylation did not alter the antiretroviral efficacy of native 3TC.
Myristoylated 3TC demonstrated reduced cytotoxicity compared with native 3TC,
which could be attributed to the increased molecular weight; the enhanced
hydrophobicity can also explain the reduced cytotoxicity since the solubility of MTC
decreased dramatically. Compared to MTC, water-soluble 3TC, which is easily ionized
in solution, can be cationized, influencing its complexation with the cell membrane,
leading to higher cytotoxicity [68].

Nanocrystals are extraordinary drug delivery carriers and are useful because of
their high drug loading capacity, improved stability and bioavailability [63, 69].
Nanosize drug crystals can be coated with surfactant for enhanced cellular uptake and
sustained cellular maintenance for long-acting efficacy. For drugs with a short half-life,
like 3TC, the therapeutic index is limited due to the low bioavailability, therefore
nanocrystals are ideal platforms for increasing drug retention and improving systemic
circulation. P407 was used as a coating surfactant in order to provide stable
nanosuspensions, improve nanoparticle dispersity, and realize long-term drug release.
Both FA-targeted and non-targeted MTC nanoparticles were prepared with welldistributed particle size and PdI. FA-NMTC exhibited a slightly larger size compared
with NMTC due to the longer chain of FA-P407 coating polymer, but otherwise no
significant difference was observed based on the characterization of the these two
formulations. Both nanoformulations were stable in PBS and sustained drug release
was observed in vitro, which demonstrated that this platform could be utilized to
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manufacture particles with stable physiochemical properties and a sustained release
profile.
The FA-NMTC nanoparticles showed better cell uptake by macrophages,
especially in the first 2 hours. These particles were expected to be taken through both
phagocytosis and receptor-mediated endocytosis. Folate derivatives are internalized
mainly through the reduced folate carrier (RFC), which binds to the reduced form of
vitamin B9; and the folate receptor (FR), which has a high affinity for folic acid [70].
There are several different isoforms of FR including FR-α and FR-β, which are
glycosylphosphatidylinositol-anchored

proteins

(GPI-AP)

receptors.

We

have

demonstrated in previous studies that FA coated nanoparticles are taken up by
macrophages

mainly

through

FR-β

due

to

its

overexpression

in

activated

macrophages during myelopoiesis [53]. Especially for HIV-1 infected patients, FR-β
will be highly expressed since the immune cells are activated [71, 72]. Meanwhile,
nanoparticles can directly activate macrophages and more FR-β could be stimulated
and overexpressed on the cell membrane of macrophages [53]. Both folate targeted
and non-targeted MTC formulations can be taken up by macrophages through clathrin
mediated endocytosis. Particles undergo recognition in the blood stream through
opsonization and the opsonized particles attach to the cell membrane and are ingested
into phagosomes [73]. The folate conjugated MTC nanoparticles are internalized by
macrophages preferentially through a clathrin-independent pathway by the effect of
FR-β. Folate attached to the MTC particles binds to GPI-anchored folate receptor, FRβ, which is overexpressed on the macrophage surface [74]. This process facilitates the
internalization of the MTC particles, which can explain the 2-fold difference after 2 h
treatment and the enhanced antiretroviral activity compared with the non-targeted
nanoformulation. Due to the enhanced cell uptake, FA-NMTC exhibited greater
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antiretroviral activity than non-targeted NMTC as confirmed by RT assay and HIV-1
p24 staining. Greater protection against HIV-1 was observed for targeted nanoparticles
and the significant differences lasted for 10 days. Equivalent antiretroviral efficacy for
both formulations by day 15 could be because most of the drug had been released by
that time; however, both formulations showed greater antiretroviral efficacy compared
with native 3TC.
It has been proved that endolysosomes can be affected by HIV-1 infection through
Rab protein expression, and endosomes are sites of active viral assembly, where a
great

amount

of

virions

accumulate

during

productive

infection

[55,

56].

Endolysosomal pathways are vital to the transport antimicrobial drugs since they
enable the drug particles to re-locate at specific sites where virus produces and
duplicates. We investigated the intracellular localization of non-targeted MTC particles
in macrophages. We found they predominantly co-localized in late (Rab 7) and
recycling (Rab 11 and 14) endosomes and lysosomes (LAMP1), which it demonstrated
that nanoMTC was taken up and stored in macrophages through the endolysosomal
pathways. MTC particles contained within endocytic compartments would provide a
protected environment to facilitate drug release with steady antiretroviral efficacy. This
not only provides effective drug delivery to HIV-1 action sites for improved therapeutic
efficacy, but also protects the particles from intracellular degradation.
To investigate the in vivo pharmacokinetic parameters of nanoformulated MTC, we
treated the mice with 50 mg/kg 3TC equivalents based as native 3TC, pro-drug MTC
or nanoformulated MTC. Nanoformulated MTC exhibited sustained drug release and
the folate coated MTC formulation exhibited 2-fold enhanced plasma and tissue drug
levels compared with non-coated formulation in. Even after two weeks, the plasma
level for FA-NMTC was still greater than three times higher than the half maximal
effective concentration (EC50) of 3TC (about 6.9 ng/mL). These studies also
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demonstrated that the targeted MTC particles were more effectively stored in the
macrophage

depots

after

injection,

as

evidenced

by

their

localization

in

reticuloendothelia tissues and lymph nodes. NanoMTC were taken by monocytes in
blood, and redistributed during systemic circulation to reticuloendothelial tissues. In
macrophages, MTC was gradually released into the endosomal compartments and
converted to native 3TC by hydrolases. In vivo MTC was efficiently converted to 3TC
since little MTC was detected in plasma and tissues. Due to effective binding to the FR
on

macrophages,

more

FA-NMTC

particles

could

be

taken

up

by

monocyte/macrophages, distributed into different cellular compartments, and avoid
degradation by lysosomes, all of which would explain the higher in vitro uptake and
more sustained in vivo pharmacokinetic behavior for FA targeted MTC particles.
2.6. Conclusions
A hydrophobic 3TC prodrug was successfully synthesized through myristoylation
and incorporated into targeted and non-targeted nanocrystalline formulation to improve
drug half-life and reduce cytotoxicity. Nanoformulated MTC exhibited enhanced
cellular uptake and sustained antiretroviral efficacy. Folate targeted MTC nanoparticles
exhibited improved pharmacokinetics and this novel drug delivery system has showed
great potentials in the clinical application.
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Figure 2.1. Characterization of myristoylated 3TC.
(A) Synthesis of myristoylated 3TC (MTC) derivative. (B) The 1H NMR spectrum of MTC.
MTC was dissolved in Dichloromethane-d2 and characterized by nuclear magnetic
resonance spectrometry (1H NMR) determined on a Varian Unity/Inova-500 NB.
Chemical shifts are reported in parts per millions (ppm). (C) FT-IR spectra of MTC and
native 3TC. MTC and 3TC powder was analyzed by Spectrum Two FT-IR Spectroscopy
to detect the structure of the final compounds. (D). Schematic diagram of the FA-NMTC
formulation. Hydrophilic 3TC was myristoylated into hydrophobic MTC, and FAP407/P407 polymer solution was used to encase MTC into FA-NMTC.
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Figure 2.2. Characterization of MTC formulations
(A) Characteristics of MTC nanoformulations. (B) Cumulative release of MTC in
isotonic solution. (C) Cytotoxicity of nanoformulated MTC. Cytotoxicity of native 3TC,
MTC and both formulations was evaluated by Cell Counting Kit-8. MDM were treated
with native 3TC, MTC, NMTC, or FA-NMTC at different concentrations for 4 h and
cytotoxicity was determined. The difference between 3TC and MTC at concentrations
1.0, 3.3, 10.0, 33.3, and 100 mM are significant (P < 0.05). (D) Time course of uptake
of MTC

formulations in

human

MDM.. MDM

were

treated

with

100

µM

nanoformulations (based on MTC content) for 1, 2, 4 and 8 h. The cell lysates at
indicated times were analyzed by HPLC for MTC quantification. Data represent the
mean ± standard error of the mean (n = 3), for each time point.
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Figure 2.3. Antiretroviral efficacy of MTC nanoformulations.
(A) HIV-1 RT activity of native 3TC and nanoformulated MTC. (B) HIV-1 p24 staining
of virus-infected MDM pretreated with native 3TC or nanoformulated MTC. MDM were
treated with 100 µM native 3TC or nanoMTC for 4 h. At days 0, 5, 10, or 15, MDM
were infected with HIV-1 for 4 h. Uninfected cells without treatment served as a
negative control; HIV-1 infected cells without treatment served as a positive control for
the RT assay. All the samples were collected after 7 days of viral infections for RT
assay and HIV-1 p24 staining. For RT activity, results are shown as the mean of 5
replicates. The differences between 3TC and nanoMTCs (NMTC and FA-NMTC) at
days 5, 10 and 15 are significant (P < 0.05). The differences between NMTC and FANMTC are significant at days 0, 5, and 10 (P < 0.05).
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Figure 2.4. Subcellular localization of nanoformulated MTC in MDM.
MDM were cultured for 7 days and treated with 100 µM CF488-labeled NMTC for 4 h.
The cells were stained with Rab 5, 7, 11, or 14 primary antibodies and AlexaFluor 568labeled secondary antibodies to visualize the corresponding cell compartments using
confocal microscopy. Nanoparticles are shown in green, cell compartments in red, and
nuclei in blue.
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Figure 2.5. Plasma drug levels of nanoformulated MTC in Balb/C mice.
(A) Scheme of the pharmacokinetic study design. (B) Plasma drug levels from 8h to
day 3. (C) Plasma drug levels from day 5 to 14. (D) Drug levels in liver, spleen and
lymph node with formulations treated mice at day 14. Mice were administered
intramuscularly (IM) 50 mg /kg equivalents of 3TC using native 3TC, MTC or MTC
nanoformulations. Plasma was collected into acetonitrile for drug analysis at 8 h, and
days 1, 3, 5, 7, 10 and 14 after treatment and tissues were collected at day 14 after
sacrifice. 3TC levels were determined by UPLC-MS/MS. Data are expressed as mean
± SEM. Statistical differences were determined using one-way ANOVA among groups.
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Chapter III.
Endolysosomal trafficking of
nanoformulated antiretroviral
therapy
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3.1. Abstract

Limitations in antiretroviral therapy (ART) include poor patient adherence, drug toxicities,
viral resistance and failures to penetrate viral reservoirs. Recent developments of
nanoformulated ART (nanoART) could overcome such limitations. To this end, we now
report a novel effect of nanoART that facilitates drug depots within intracellular
compartments at sites at or adjacent to the viral replication cycle. Poloxamer 407 coated
nanocrystals containing the protease inhibitor atazanavir (ATV) were prepared by highpressure homogenization. These drug particles readily accumulated in human
monocyte-derived macrophages (MDM). NanoATV concentrations were ~1,000 times
higher in cells than what could be achieved by native drug. ATV particles in late and
recycling endosome compartments were seen following pull down by immunoaffinity
chromatography with Rab-specific antibodies conjugated to magnetic beads. Confocal
microscopy provided cross validation by immunofluorescent staining of compartments.
Mathematical modeling validated drug-endosomal interactions. Measures of reverse
transcriptase activity and HIV-1p24 levels in culture media and cells showed that such
endosomal drug concentrations enhanced antiviral responses up to 1,000 fold. We
conclude that late and recycling endosomes can serve as depots for nanoATV. The colocalization of nanoATV at endosomal sites of viral assembly and its slow release sped
antiretroviral activities. Long acting nanoART can serve as a drug carrier in both cells
and subcellular compartments and as such facilitate viral clearance. The need for long
acting ART is significant and highlighted by limitations in drug access, toxicity,
adherence and reservoir penetrance. We propose that targeting nanoformulated drugs
to infected tissues, cells and subcellular sites of viral replication may improve clinical
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outcomes. Endosomes are sites for human immunodeficiency virus assembly and
increasing ART concentration to such sites enhances viral clearance. The current work
uncovers a new mechanism for why nanoART can enhance viral clearance over native
drug formulations.

3.2. Introduction
Long-acting nanoformulated antiretroviral therapy (nanoART) can result in improved
patient adherence, decreased systemic toxicities and sustained viral suppression. This is
seen through nanoART’s abilities to maintain consistent plasma and tissue drug levels
[75-78]. Nonetheless, to facilitate clearance of the human immunodeficiency virus type
one (HIV-1), antiretroviral drugs need be effectively delivered to viral sanctuaries [62].
This can target persistent or restricted infection [53, 79, 80]. With this in mind, our
laboratories pioneered the use of monocytes and monocyte-derived macrophages (MDM)
as nanoART carriers and drug depots. Macrophages can increase drug stability by
preventing drug metabolic degradation and because of their highly mobile nature, they
may also be used for delivery of ART to and from lymphocytes and other viral reservoirs
[81-83]. How drug nanoparticles remain sequestered in macrophages for extended
periods is incompletely understood. What is known is that nanoART can be delivered to
endosomal organelles through clathrin-endosome pathways and remain inside the cell
for extended time periods [81]. However, the virologic consequences of such a cell
delivery system have not yet been elucidated. Investigations of nanoparticle interactions
at the subcellular level remain of vital importance to the fields of long-acting antiretroviral
pharmacokinetics and pharmacodynamics.
We reasoned that such mechanisms could be elucidated through investigations of
nanoformulated viral protease inhibitors (PI). PI are substrate analogs for the HIV
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aspartyl protease enzyme, involved in processing viral proteins by cleaving precursor
proteins into smaller fragments and enabling the release of mature viral particles from
infected cells. Once bound to the active site, they block the viral protease and in turn
inhibit viral maturation, which blocks the formation of replication competent virions [84,
85]. Atazanavir (ATV), a United States Food and Drug Administration-approved PI for
the treatment of HIV-1 infection can selectively inhibit virus-specific processing of gagpol polyproteins. As a consequence PIs block viral assembly at action sites [86].
It is well known that subcellular organelles are utilized for HIV-1 assembly in
mononuclear phagocytes (MP; monocytes and tissue macrophages) [87, 88]. Indeed,
large caches of infectious HIV-1 released from MDM are produced in late endosomes
[89]. We thus reasoned that if nanoART can improve drug delivery to tissues and cells
and affect viral clearance, its effects could be amplified if the PI is delivered to the late
endosomal sites operative for viral assembly. Herein, we demonstrate that nanoART
enhances its antiretroviral efficacy by being delivered to subcellular sites of active viral
replication. By tracking endosomal nanoART transport, sequential immunoaffinity
separations

of

cellular

compartments

and

by

developing

computer

assisted

mathematical models we were able to track the antiretroviral drug activities inside
macrophages. Antiretroviral responses as measured by reverse transcriptase (RT)
activityand HIV-1p24 antigen provided evidence for the co-localization of nanoART and
progeny virus. Mathematical modeling uncovered the pathways for nanoparticle
trafficking

through

endosomal

compartments

[90].

Previous

combinations

of

experimental and computational studies were limited by the inherent complexity of
integrating simulated modals with experimental results [91]. The nanoparticle-subcellular
compartment modeling supports the idea that nanoformulations can facilitate the use of
macrophages as drug carriers for ART and thus facilitate the establishment of drug
depots and speed of viral clearance.
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3.3. Materials and methods
3.3.1. Reagents & antibodies
ATV sulfate purchased from Longshem Co (Shanghai, China) was free-based with
triethylamine. Poloxamer 407 (P407) and CF568-succinimidyl ester (CF568) were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Sephadex LH-20 was obtained from
GE HealthCare (Piscataway, NJ, USA). Pooled human serum was obtained from
Innovative Biologics (Herndon, VA, USA). Macrophage colony stimulating factor (MCSF)
was prepared from 5/9m alpha3-18 cells (ATCC®, CRL-10154TM) cultured in ATCC
complete growth medium as described [20]. Rabbit anti-human antibodies to Rab5,
Rab7, Rab11 and Rab14, and Alexa Fluor 488 goat anti-rabbit IgG were purchased from
Santa Cruz Biotechnology (Dallas, TX, USA). Protein A/G mix magnetic beads were
purchased from Millipore (Billerica, MA, USA). TRIzol reagent was obtained from
Invitrogen (Grand Island, NY, USA).
3.3.2. NanoATV manufacture and characterization
ATV nanoparticles were formulated by high-pressure homogenization (Avestin
EmulsiFlex-C3, Avestin Inc., Ottawa, ON, Canada) using P407 to encase the drug
crystals. The suspension containing free-based ATV (1%, w/v) and P407 (0.5%, w/v) in
10 mM HEPES buffer was premixed overnight at room temperature then homogenized
at 20,000 psi for ~30 passes until the desired particle size of <300 nm was achieved.
Size, zeta-potential and polydispersity (PDI) were determined by dynamic light scattering
(DLS) using a Malvern Zetasizer Nano Series Nano-ZS (Malvern Instruments,
Westborough, MA, USA). A minimum of four iterations were taken and these varied by <
2%. After reaching the desired size (< 300 nm) the sample was purified by centrifugation
at 500 × g for 5 min to remove aggregated particles, then at 10,000 × g for 30 min to
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collect a purified particle pellet. The resulting particles were resuspended in a 0.2% (w/v)
P407 surfactant solution for cell studies.
3.3.3. Synthesis of dye-labeled nanoATV
For preparation of CF568-labeled nanoATV, CF568-P407 and P407 were dissolved in
methanol at a weight ratio of 1:4 [6]. The solvent was evaporated and the mixture
resuspended with 10mM HEPES to yield a 0.5% surfactant solution. Free-based ATV
was added at a 1% weight ratio. The suspension was premixed overnight in a light
protected environment at room temperature. The suspension was homogenized by highpressure homogenization and purified by centrifugation [10].
3.3.4. Human monocyte isolation and cultivation
Human monocytes were obtained by leukapheresis from HIV-1,2 and hepatitis B
seronegative donors then purified by counter-current centrifugal elutriation. The
recovered monocytes, >98% pure by Wright stained cytosmears, were cultured in
Dulbecco’s Modified Eagle’s Media (DMEM) with 10% heat-inactivated pooled human
serum, 1% glutamine, 50 µg/mL gentamicin, 10 µg/mL ciprofloxacin and 1000 U/mL
recombinant human MCSF for seven days facilitating cell differentiation into
macrophages (MDM) [57].
3.3.5. Native and nanoformulated ATV cell uptake and retention
MDM were treated with native ATV or nanoATV at 30 or 70 µg/ml. Uptake of drug was
assessed without media change for 24h. Cell collection occurred at serial time points.
After 24 h drug exposure, drug retention in MDM was evaluated. Adherent MDM were
collected by washing 3X with 1 mL of phosphate buffered saline (PBS), followed by
scraping cells into 1 mL PBS. Samples were centrifuged at 950 × g for 10 min and
supernatant removed. The cell pellets were resuspended in 200 µL methanol and
56

sonicated with a probe sonicator. The methanol extracts were centrifuged at 20,000 × g
for 10 min prior to high performance liquid chromatography (HPLC) analysis as
previously described [63]. Triplicate 20 µL samples of cells were assessed by HPLC
using a YMC Pack Octyl C8 column (Waters Inc., Millford, MA) with a C8 guard
cartridge. Mobile phase consisting of 47% acetonitrile/53% 25mM KH2PO4, pH 4.15, was
pumped at 0.4 mL/min with UV/Vis detection at 212 nm. ATV levels in cells were
determined by peak area comparisons to those of a standard curve generated with free
drug (0.025-50 µg/mL).
3.3.6. Immune isolation of endocytic subcellular compartments
Immune isolation of endocytic compartments was performed as previously described
[81]. Briefly, MDM were treated with native or nanoATV for 16 h. Cells were washed 3X
in PBS to remove extracellular drug and then scraped in homogenization buffer (10 mM
HEPS-KOH, pH 7.2, 250 mM sucrose, 1 mM EDTA, and 1 mM Mg(OAc)2). Cells were
then disrupted by 15 strokes in a dounce homogenizer. Nuclei and unbroken cells were
removed by centrifugation at 400 × g for 10 min at 40C. Twenty µL of slurry protein A/G
paramagnetic beads conjugated to Rab 5, 7, 11 or 14 antibodies (binding in 10% BSA in
PBS for 12 h at 40C) were incubated with cell supernatants. Following a 24 h incubation
at 40C, Rab 5, 7, 11, and 14+ endocytic compartments were washed with PBS then
collected on a magnetic separator. The drug content of each compartment was
determined by HPLC [81].
3.3.7. Detection of HIV-1 integration by polymerase chain reaction (PCR)
To estimate the HIV integration, a modified method of that developed by O’Diherty and
colleagues was employed [92]. After seven days of culture, MDM were treated with 100
µM native or nanoATV for 16 h then challenged with HIV-1ADA at a multiplicity of infection
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(MOI) of 0.1 infectious viral particles/cell. Following viral infection for 4 h, cells were
cultured for an additional 14 days with half media exchanges every other day before the
cells were scraped for collection. TRIzol Reagent was used to isolate DNA and RNA
samples. The number of proviruses/cell was determined by a kinetic PCR assay. The
standard curve was derived by running the nested PCR protocol on several dilutions of
the integrated standard nucleic acid samples [93]. The concentrations of human
genomes in the isolated sample DNA (or RNA) were determined by OD260/280.
3.3.8. Antiretroviral activities
Antiretroviral efficacy was determined by HIV-1 RT activity [57, 94]. Briefly, MDM were
treated with 100 µM native- or nano-ATV for 16 h and then challenged with HIV-1ADA at a
MOI of 0.1. Following viral infection, cells were cultured for 14 days with half media
exchanges every other day. Medium samples were collected on days 2, 4, 6, 8, 10, 12
and 14 for measurement of progeny virion production as assayed by RT activity. Here,
10 µL media samples were mixed with 10 µL of a solution containing 100 mM Tris-HCl
(pH 7.9), 300 mM KCl, 100 mM dithiothreitol, 0.1% nonyl phenoxylpolyethoxylethanol-40
(NP-40) and water in a 96-well plate. The reaction mixture was incubated at 370C for 15
min and 25 µL of a solution containing 50 mM Tris-HCl (pH 7.9), 150 mM KCl, 5 mM
dithiothreitol, 15 mM MgCl2, 0.05% NP-40, 10 µL/mL poly(A), 0.25 U/mL oligo d(T), and
10 µCi/mL 3H-thymidine triphosphate was added to each well; plates were incubated at
370C for 18 h. Following incubation, 50 µL of cold 10% TCA was added to each well, the
wells were harvested onto glass fiber filters, and the filters were assessed for 3Hthymidine triphosphate incorporation by beta-scintillation spectroscopy using a TopCount
NXT (PerkinElmer Inc., Waltham, MA, USA).
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3.3.9. Immunocytochemistry and confocal microscopy
For immunofluorescence staining, cells were washed three times with PBS and fixed
with 4% paraformaldehyde (PFA) at room temperature for 30 min. Cells were treated
with blocking/permeabilizing solution (0.1% Triton, 5% bovine serum albumin (BSA) in
PBS) and quenched with 50 mM NH4Cl for 15 min. Cells were washed once with 0.1%
Triton in PBS and sequentially incubated with primary and secondary antibody at room
temperature. Slides were covered in ProLong Gold anti-fading reagent with DAPI and
imaged using a 63× oil lens in a LSM 510 confocal microscope (Carl Zeiss
Microimaging, Inc., Dublin, CA, USA) [28].
3.3.10. HIV-1p24 staining
Cells in different treatment groups were fixed with 4% phosphate-buffered PFA for 15
min at room temperature. Fixed cells were blocked with 10% BSA in PBS containing 1%
Triton X-100 for 30 min at room temperature and incubated with mouse monoclonal
antibodies to HIV-1p24 (1:100; Dako, Carpinteria, CA, USA) for 3 h at room temperature.
Binding of HIV-1p24 antibody was detected using a Dako EnVision+ System-HRP
labeled polymer anti-mouse secondary antibody and diaminobenzidine staining. Cell
nuclei were counter stained with hematoxylin for 60 s. Images were taken using a Nikon
TE300 microscope with a 40 × objective. Quantitation of immunostaining was performed
by densitometry using ImagePro Plus, v. 4.0 [95].

3.4. Results
3.4.1. NanoART characterization
The nanoATV particles were formulated as a nanosized drug crystal from free-base
ATV and P407. Physical properties including size, PDI and zeta potential were
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measured by DLS. The particle size was 371.7 nm with a PDI of 0.194, which indicated
the majority of nanoATV particles were homogeneous. The zeta potential was -28.9 mV,
and the negative charge was contributed by P407.

Scanning electron microscopy

revealed smooth rod-like morphologies for the nanoATV particles and confirmed size
measurements and distribution, which was consistent with our previous studies [81, 82].
3.4.2. Native and nanoATV cell uptake and retention
MDM uptake and retention of drug were assessed by HPLC. Cells were exposed to
native ATV or nanoATV for 24 h and two treatment concentrations (30 and 70 µg/mL)
were used. Significant differences were observed in rate and extent of drug uptake
between native and nanoATV treatment groups (Figure 3.1A). The uptake of nanoATV
was found to increase with time and the maximum uptake was observed at 16 h for 70
µg/mL treatment group (53.5 µg ATV/106 cells) and 24 h for 30 µg/mL (23.7 µg ATV/106
cells). However, uptake of less than 0.1 µg ATV/106 cells was observed at 24 h for both
native ATV treatment groups, and this was not time-dependent. Drug retention in MDM
was determined 24 h after treatment. In MDM treated with nanoATV, drug levels of 28.5
µg/106 cells and 14.0 µg/106 cells in 70 and 30 µg/mL treatment groups, respectively,
were sustained over 24 h. Sustained release was expected for up to 15 days with
nanoparticle treatment based on previous studies [53, 82]. Much less ATV was detected
24 h following treatment with native ATV.
3.4.3. Antiretroviral activities of native and nanoATV
To estimate the level of HIV-1 DNA and RNA PCR amplification assays were employed.
After seven days of cultivation, MDM were treated with 100 µM native or nanoATV for 16
h then challenged with HIV-1ADA at a MOI of 0.1. Following infection, cells were cultured
for 14 days with half media exchanges every other day before cell collections. Isolated
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total cell DNA or RNA were quantitated by kinetic PCR and nucleic acid levels calculated
using standard curves made by the linear regression analyses. These data are shown in
Figure 3.1C and D. At day 14 after HIV-1 challenge, 1.15 × 104 and 1.05 × 104 viral
copies/103 MDM of viral DNA and RNA, respectively were determined in infected
samples. Viral copies paralleled the concentrations of native ATV where 1 µM of ATV
failed to show significant antiretroviral activity. In contrast for nanoATV treated groups,
viral DNA and RNA was effectively suppressed at 1 µM. Viral copies were 29.59 and
36.09/103 MDM for HIV-1 DNA and RNA, respectively. This was seen following 100 µM
nanoATV treatment, which effectively suppressed viral replication.
To determine the levels of progeny virus produced in native and nanoATV treated
cultures we treated MDM with native or nanoATV in increasing drug concentrations of
0.01, 0.1, 1, 10, and 100 µM. Treatment was for 16 h with subsequent HIV-1ADA
challenge at a MOI of 0.1. The same formulation used for cell uptake and retention was
tested for antiretroviral activities to ensure that the results were comparable. Infected
cells were cultured for 14 days with half media change every other day. Culture
supernatants were collected at days 2, 4, 6, 8, 10, 12, and 14 for determination of
progeny virion production assayed by RT activity. A dose-dependent effect on RT
activity for native and nanoATV at all time points was observed (Figure 3.1E and F).
Significant differences between native and nanoATV were seen. For native ATV treated
cells, suppression of RT activity was maintained over time only at 100 µM, and most of
the other native drug concentrations failed to show significant viral suppression
compared to untreated controls. In contrast, nanoATV reduced RT activity effectively
starting at 1 µM. A two-log increase in viral suppression was seen with nanoATV as
compared to native ATV.
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3.4.4. NanoATV effects on HIV-1 p24 antigen
Cross validation of the results shown above was made through evaluation of viral
antigen expression following native and nanoATV treatments for infected cell cultures.
The expression of HIV-1 p24 antigen was used to determine antiretroviral activity in
MDM that were treated with native or nanoATV and subsequently challenged with HIV-1
at a MOI of 0.1. Evaluation of p24 expression by infected MDM treated with native or
nanoATV showed a concentration-response effect on the HIV-1 p24 expression at day
14 following viral exposure (Figure 3.2). Higher treatment concentrations resulted in
lower p24 expression for both treatment groups. Formation of multinucleated giant cells
was also observed. Significant differences between the native and nanoATV were seen
at all concentrations. The expression of HIV-1 p24 antigen decreased slightly in cells
treated with 1 or 10 µM native ATV, but an 89.4% decrease was found in cells treated
with 100 µM native ATV (data not shown). HIV-1 p24 expression in cells was reduced
with all concentrations of nanoATV. Viral suppression was to nearly asymptomatic levels
with nanoATV treatment; i.e. 90.9, 94.2 and 95.7% for 1, 10 and 100 µM nanoATV
treatment, respectively (data not shown).
3.4.5. NanoATV subcellular distributions
Confocal microscopy enabled both visualization and quantitation of the subcellular
nanoATV distribution in early (Rab 5), late (Rab 7) and recycling (Rab 11, 14) endocytic
compartments [96]. In these experiments, MDM were treated with 100 µM nanoATV
fluorescently labeled with CF568. Immunostaining was performed 16 h after particle
incubation for visualization of endocytic compartments and nanoATV co-localization.
These experiments showed nanoATV distribution in a punctate pattern throughout the
cytoplasm and perinuclear cell regions. NanoATV was found predominantly in late and
recycling endosomes of uninfected macrophages (Figure 3.3A). Quantitation of the
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fluorophore labeled Rab species in endosomes with CF568 (fluorescent)-labeled
nanoATV was made by adapting Pearson’s correlation coefficient to measure only
positive co-localization coefficients (i.e. M1 and M2) of the two fluorophores at different
emission wavelengths. Based on this, we showed significant accumulation (p< 0.001) of
nanoATV within Rab 5- (35.4 ± 5%), Rab 7- (65.1 ± 7%), Rab 11- (70.3 ± 11%) and Rab
14- (56.9 ± 12%), positive compartments. To assess subcellular co-localization of
nanoATV with assembled HIV-1 virions, MDM were treated with 100µM CF568-labeled
nanoATV for 16 h following 14 days of HIV-1ADA infection. Identical Rab-specific
antibodies were employed to immunostain endocytic compartments in multinucleated
giant cells. Quantitation of fluorophore in Rab compartments showed clear colocalization between virus and the nanoparticles (Figure 3.3B and 3D). The greatest
amount of dual co-localization was found in Rab 7-immunopositive late endosomes.
These data indicated that after HIV-1 infection, nanoATV persists in late endosomal
compartments, the site of active viral assembly, but at half the level present in recycling
endosomes of uninfected macrophages (3.3C vs. 3.3D).
3.4.6. NanoATV trafficking in endosomal subcellular comparments
To assess the locale of nanoATV at the subcellular level we analyzed individual
endosomal compartments within MDM by immunoaffinity techniques. MDM exposed to
nanoATV were mechanically disrupted at specific time points, and subcellular
compartments including early, late and recycling endosomes were immunoisolated using
A/G paramagnetic beads conjugated to Rab 5, 7, 11 or 14 antibodies. Endocytic
compartments bound to beads were collected by magnetic separation, digitally imaged
and then analyzed by HPLC for drug content. Time dependent endocytic uptake was
observed in all labeled endosomes and the data was used to generate 48 h subcellular
uptake curves (Figure 3.4A). At 48 h, the maximum nanoATV uptake was 10.6 ± 1.4
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µg/106 cells in Rab 14 (early recycling endosomes) compartments, followed by 8.3 ± 0.7
µg/million cells in Rab 11 (late recycling endosomes) compartments. The lowest
nanoATV concentration was found in Rab 5 compartments, representing early
endosomes, regardless of HIV-1 infection, which was consistent with the co-localization
confocal microscopy tests.
3.4.7. Simulation of nanoATV at the subcellular level
Mathematical means to simulate drug particle uptake and retention at both the cellular
and subcellular levels were developed based upon our results. These models
demonstrated

that

trafficking

of

nanoformulated

particles

in

endosomal

cell

compartments provided an accurate and reliable view of their behavior in real time. The
drug levels in specific compartments at different time points together with the
confirmation that more nanoATV than native ATV could accumulate in late and recycling
endosomes proved these to be the major subcellular depots for nanoATV. The modeled
flow of nanoparticles is presented in Figure 3.4C where outside of the cell and the
specific subcellular compartments involved in trafficking of the majority of nanoATV are
represented as the graph nodes: ‘Out’ – the outside of the cell, ‘Rab5’, ‘Rab7’, ‘Rab11’,
and ‘Rab14’ – denoting the compartments identified by the respective Rab proteins. The
instantaneous concentration of nanoATV outside the cell, Q1, is associated with the node
‘Out’, and the instantaneous concentrations of respective Rab proteins, Q2, …, Q5, are
associated with the nodes ‘Rab5’, ‘Rab7’, ‘Rab11’, and ‘Rab14’. It has been noticed that
the total number of the observed nanoATV/fluorescent labeled particles in the
experiment decreases over time. This has been taken to account in the model as an
open path marked δ in the graph of Figure 3.4C.
Based on the graph topology, the time changes of the concentrations in the model are
controlled by the set of 5 difference equations:
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where ΔT denotes the time increment in simulations, and (·)(j) denotes the value of (·) at
jth step of simulation.
Based on the experimental results, using multiple linear regression, and curve fitting
methods implemented as standard MATLAB functions, the following relationships
between the concentrations Q1, …, Q5, and the rates of changes V1, …, V8 were
established:
𝑉! = 0.04269𝑄! + 0.7778
𝑉! = 0.1000𝑄! − 0.085𝑄! + 0.0814
𝑉! = 0.0367𝑄! − 0.2714𝑄! + 2.238
𝑉! = 0.003𝑄! + 0.0367𝑄! − 0.155𝑄! − 0.1263𝑄! + 0.7366
𝑉! = −0.003𝑄! + 0.155𝑄! − 0.33
𝑉! = −0.0031𝑄! + 0.2344𝑄! − 0.22
𝑉! = −0.0031𝑄! + 0.01785𝑄! − 0.112
𝑉! = 0.01exp (0.01𝑡)𝑄!
where t is time from the experiment start. The units for all the rates are µg/106 cells/h and
µg/106 cells for concentrations. The simulation model based on the set of difference
equations was implemented in MATLAB using similar technique as applied in [97].
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3.4.8. Subcellular antiretroviral activity
To determine in which compartments the virus persists and the antiretroviral efficacy of
our nanoATV at a subcellular level, MDMs were challenged with HIV-1ADA for 4 h at a
MOI of 0.1, then treated with 100 µM native ATV or nanoATV for 16 h. MDM were
mechanically disrupted at days 7 and 14, and subcellular compartments were
immunoisolated using A/G paramagnetic beads conjugated to Rab 5, 7, 11 or 14
antibodies. Endocytic compartments bound to beads were collected by magnetic
separation for the RT assay. The highest RT activity was found in Rab 11
compartments,

representing

recycling

endosomes,

and

Rab

7

compartments,

representing late endosomes, in non-treated cells after 7 and 14 days of HIV-1 challenge
(Figure 3.5B), respectively, which suggested that virus located mainly in these
endosomal compartments. NanoATV and native ATV at 100 µM both exhibited
antiretroviral efficacy, while nanoATV more effectively decreased RT activity in all
endosome compartments, especially Rab 7 and 11 fractions. Based on the confocal
results, greater overlap of nanoATV and cellular compartments was found in late and
recycling endosomes, which could explain why nanoATV was more effective in
suppressing HIV-1 virus in these compartments.

3.5. Discussion
Nanocrystals are broadly used for drug delivery due to their high drug loading capacity,
increased dissolution in solution and enhanced bioavailability [98-101]. Herein, we report
the manufacture of P407 coated nanocrystal ATV (nanoATV) by homogenization and
show that its physical properties, including size and surface charge, facilitate
macrophage particle uptake and drug stability. Indeed, nanoATV was readily internalized
by macrophages and produced sustained drug release. This serves to improve drug
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efficacy by increasing subcellular bioavailability. Nanosized drug crystals coated with
surfactant exhibit enhanced cellular uptake and facilitate the cellular maintenance of
drug particles for prolonged time periods. Particle coating serves to increase intracellular
drug stability. Notably, nanoATV leads to effective inhibition of HIV-1 replication for
prolonged time periods. In contrast to native ATV, nanoATV shows weeks of viral
suppression linked to its abilities to increase drug delivery to subcellular macrophage
compartments. This is facilitated by sustained antiretroviral drug release rates.
Interestingly, HIV-1 infection affects the size and or number of endosomes as
reflective of Rab protein expression (G. Zhang, preliminary communication). We posit
that such virus-induced alterations in endosomes are biologically relevant to sustain viral
growth.

Indeed, endosomes are sites of active viral assembly and are the cellular

substructures where large numbers of virions accumulate during productive infection
[89].

Such a function has added strategic advantages for the nanoformulated

antiretroviral drug as it enables the drug particle to reside in the identical site where viral
maturation occurs in the cell. Taken together, such events certainly facilitate
antiretroviral drug activities. This may also be operative for a broad number of
endosomal compartments that affect “transport” of anti-microbial drugs and is likely a
common pathway for macrophage scavenging functions. Notwithstanding we also
accept that the pathways for endosomal trafficking and HIV are not perfectly congruent.
Further investigations will determine the mechanisms behind each trafficking scheme.
Such observations, nonetheless, open the means to improve antimicrobial therapies
beyond what is being reported in the current study.
Over the past decade our laboratory has pioneered the development of long-acting
nanoART. NanoATV serves as a model for macrophage-based nanoparticle drug
delivery as descriptions of cell uptake and intracellular localization of ART content
parallel one another. To better understand formulation trafficking at the cellular and
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subcellular levels, we developed a mathematical means to simulate endosomal
trafficking [90]. The model is simple to implement and can provide assessment of
“putative” drug activities based on changes in concentration of nanoATV and/or Rab
proteins in real time. Based on the model, divergent behaviors between native and
nanoATV were readily observed. NanoATV was taken up efficiently into macrophages
and effected sustained drug release while native ATV was minimally internalized. This
helps to explain why nanoATV possesses distinct long-acting antiretroviral efficacy.
Through our subcellular uptake simulation model, nanoATV subcellular distributions
were visualized, and late and recycling endosomes were considered as the nanoATV
depots. Indeed, large amounts of nanoATV were deposited in these endocytic
compartments. However, it is also noted that differences exist between HIV-1 and
nanoparticle drug subcellular accumulation including recycling endosomes. Whether this
is a clever means of virus altering the “transport” properties of nanoparticles or a
compensatory host mechanism in attempts to contain virus is not yet known. Further
studies are certainly needed to assess the unique transport properties of the virus and
the drug-laden particle.
Harnessing macrophage transport properties for drug delivery can improve clinical
drug responses. Indeed, cell-based nanocarriers have been developed for not only
cancer chemotherapy but also a wide range of microbial infections [102-104].
Macrophage-based nanomedicine delivery schemes may have several advantages over
more conventional drug delivery including enhanced cure rates, reduced side effects,
increased drug stability and effective subcellular targeting [28, 95, 105, 106]. Using the
macrophages as a nanocarriage vehicle can permit investigations of nanoATV entry,
intracellular trafficking and drug release kinetics.
NanoATV

contained

within

endocytic

compartments

provide

a

protected

environment to facilitate drug release with unaltered antiretroviral activities. Both late and
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recycling endosomes were able to retain a large number of the nanoparticles.
Macrophages likely play a vital role in HIV pathogenesis as they are among the first cells
infected [107, 108]. Within an infected macrophage, virions are formed in a temporally
and spatially coordinated manner wherein the components that make up the virus
assemble in association with a specific cellular membrane from which the viral envelope
is derived [89]. HIV-1 virions bud directly into late endosomes and thereby acquire late
endosomal membrane proteins, such as Rab 7, LAMP-1 and CD63 [88]. Macrophages
secrete virions from virus-containing intracellular vacuoles [109]. Late endosomes are
principal locales for HIV assembly [110-114]. Importantly, nanoATV retains full
antiretroviral activity in late endosomes, as RT activity was significantly decreased in
Rab 7 and Rab 11 vesicles.
In summary our results demonstrate that nanoATV and HIV target overlapping
subcellular compartments. Entry of virus and particles inside macrophages tis facilitated
through clathrin-mediated pathways [115-118]. NanoATV particles are stored within late
endosomes or recycling compartments, which serves to minimize intracellular
degradation. For release, nanoATV are slowly recycled to the plasma membrane [119122]. This provides a means for escape from phagolysosomal degradation and effective
delivery of drug to action sites, which in the end has a net effect of improved therapeutic
efficacy.

3.6. Conclusions
NanoATV is now demonstrated to effect increases in cellular drug uptake and retention
in macrophages. The long acting antiretroviral efficacy of crystalline nanoformulated
drugs is significantly enhanced over its native counterparts. Macrophages act as carriers
of nanoATV to improve drug bioavailability. Computer assisted mathematical modeling
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can simulate subcellular trafficking of nanoATV to late and recycling endosomes that
serve as drug particle depots. Overall, nanoATV and HIV utilize similar subcellular
pathways. Delivery of drug through subcellular compartments increases its antiretroviral
responses.
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Figure 3.1. Comparisons of native and nanoATV cellular drug uptake and
antiretroviral activity.
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(A) Time course for monocyte-derived macrophage (MDM) uptake of native or nanoATV
are illustrated. MDM cultures were treated with native or nanoATV for 24 h. (B)
Computational simulation of the time course of MDM drug uptake and retention. After 24
h treatment with native or nanoATV, cells were washed with PBS and treated with fresh
medium for 24 h. HIV-1 (C) DNA and (D) RNA levels were quantitated 14 days after
infection in MDM treated with various concentrations of native or nanoATV. The units for
viral DNA and RNA are copies/103 cells and copies/cell, separately. HIV reverse
transcriptase (RT) activity 14 days after HIV-1 infection in MDM treated with various
concentrations of (E) native- or (F) nanoATV. Data are expressed as average +/- SEM
for N=5 replicates.
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Figure 3.2. HIV-1p24 staining of virus-infected MDM pre-treated with native or
nanoATV.
MDM were treated with native or nanoATV for 16 h then challenged with HIV-1 at a MOI
of 0.1. Infection was allowed to continue for 14 days. The treatment groups included: (A)
HIV-1 infected controls; (B-D) 1, 10 and 100 µM native ATV, respectively; (E-G) 1, 10
and 100 µM nanoATV, respectively; (H) uninfected MDM.
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Figure 3.3. NanoATV subcellular distribution.
(A) Uninfected MDM and (B) HIV-1 infected MDM were treated with 100 µM, dyelabeled nanoATV for 16 h then immunostained with Rab 5, 7, 11 or 14 antibodies and
AlexaFluor 488-labeled secondary antibody (green) to visualize particle and organelle
co-registration. Quantitation of the overlap of nanoATV and Rab proteins in (C)
uninfected and (D) HIV-1 infected MDM are shown. Data are expressed as the average
+/- SEM of N=10 replicates.
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Figure 3.4. Kinetics of particle trafficking in subcellular endosomes.
(A) Subcellular uptake in different compartments in MDM treated with 100 µM nanoATV
over 48 h. (B) Simulated subcellular nanoATV uptake activity in different compartments
over the same time frame. (C) Simulated subcellular nanoATV uptake pathways. Data
are expressed as average +/- SEM of N=3 replicates.
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Figure 3.5. Intracellular pathways for HIV-1 progeny virion production and
nanoATV trafficking.
(A) Schematic diagram for HIV-1 and nanoATV trafficking. HIV reverse transcriptase (RT)
activity in subcellular endosomal compartments is shown. MDM were infected with HIV-1
for 4 h then treated with 100 µM native or nanoATV for 16 h. Endosomal compartments
were isolated using specific Rab antibody-coated magnetic beads and RT activity was
measured in endosomal compartments on (B) day 7 and (C) day 14 after infection. R5,
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R7, R11, R14: Rab 5, 7, 11 and 14, respectively. Data are expressed as the average of
N=5 replicates.
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Chapter IV.
Opposing regulation of
endolysosomal pathways by
long-acting nanoformulated
antiretroviral therapy
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4.1. Abstract
Long-acting nanoformulated antiretroviral therapy (nanoART) is designed to improve
subject regimen adherence, reduce systemic drug toxicities, and facilitate clearance of
human immunodeficiency virus type one (HIV-1) infections. While nanoART establishes
drug depots within recycling and late monocyte-macrophage endosomes, whether or not
this provides a strategic advantage to eliminate the virus is not been completely
elucidated. To this end, we applied quantitative SWATH-MS proteomics and cell profiling
to nanoparticle atazanavir (nanoATV)-treated and HIV-1 infected human monocytederived macrophages (MDM). Native ATV and uninfected cells served as controls.
Surprisingly, both HIV-1 and nanoATV engaged the endolysosomal trafficking for their
assembly and depot formation, respectively. Notably, the pathways were deregulated in
opposing manners by the virus and the nanoATV likely by viral clearance. Paired-sample
z-scores, of the proteomic data sets, showed up- and down- regulation of Rab-linked
endolysosomal proteins. NanoART and native ATV treated uninfected cells showed
limited effects. The data was confirmed by Western blot. DAVID and KEGG
bioinformatics tools showed relationships between secretory, mobility and phagocytic
cell cell functions and virus and particle trafficking. We posit that modulation of
endolysosomal pathways by antiretroviral nanoparticles provides strategic path to
combat HIV infection.

4.2. Introduction
Long acting nanoformulated antiretroviral therapy (nanoART) is emerging as an
important part of the treatment armamentarium for human immunodeficiency virus type
one (HIV-1) infection [123-126]. While our prior studies defined both a platform for drug
delivery and the trafficking mechanisms operative for nanoART in monocyte80

macrophages, how these cells can be harnessed as drug depots for improved
antiretroviral responses has not been realized [55, 62, 63, 95, 127]. Indeed, human
monocyte-derived macrophages (MDM) serve as nanoART carriers extending ART halflife and drug stability [35, 81]. Such cell-based drug delivery strategies may also
decrease systemic drug toxicities [53, 128]. We posit that endolysosomal pathways can
serve as Trojan horses for viral persistence or as vehicles for its elimination. If correct,
facilitated viral replication and the means to eliminate it may occur at identical subcellular
locales. The operative nanoART response would facilitate drug delivery by bringing the
medicine to the site of action within mononuclear phagocytes (MP; monocytes,
macrophages and dendritic cells). To investigate a seemingly mechanistic paradox,
functional proteomic tests were employed to uncover how drug particles affect the HIV-1
replication cycle beyond nanoART activity.
The intracellular trafficking pathways held by the virus and nanoART were investigated
by Sequential Windowed data independent Acquisition of the Total High-resolution Mass
Spectra (SWATH-MS) profiling. This technique was applied to obtain a broader picture
of complex nanoART-HIV interactions. The method was previously employed in our and
other laboratories to identify and quantify cellular peptides on a larger scale [129-133].
While past transcriptomic and proteomic analyses were applied to study virus-cell
interactions [130-133], they have failed to uncover key proteins affected by targeted
antiretroviral treatments. Herein, we identified deregulated cellular proteins affected by
nanoatazanavir (nanoATV) in HIV-1-infected MDM. Comparison was made between
formulated and native ATV by the effect of HIV-1. Common cellular proteins with
coordinated molecular, biochemical and biological functions were altered in virusinfected and nanoATV treated cells. These were linked to phagosome signalling
pathways specifically associated with the endosomal and lysosomal compartments.
Specifically, opposing expressions of Rab7 and -11 and LAMP1 were seen in HIV-1
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infected and nanoATV-treated cells. Notably, the downregulation of late and recycling
endosomes and LAMP1, indicated that pathways that could be employed, in measure,
for viral assembly and nanoparticle lysosomal degradation were affected. Through cross
validation of proteomics, cell biology and protein chemistry, our data provide novel
insights into how nanoART facilitates viral clearance while establishing long-lived cellbased depots different from native drug. These works represent a previously unknown
mechanism for how long-acting nanoART provides a strategic advantage to combat viral
infection.

4.3. Materials and methods
4.3.1. Reagents and Antibodies
ATV sulfate (Gyma Laboratories of America Inc., Westbury, NY, USA) was free based
with triethylamine. Poloxamer 407 (P407) and CF568-succinimidyl ester (CF568) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Human serum was obtained from
Innovative Biologics (Herndon, VA, USA). Macrophage colony-stimulating factor (MCSF)
was prepared from 5/9m alpha3-18 cells (ATCC; CRL-10154) [54]. Rabbit anti-human
Rab 5, -7, -11, LAMP1 and β-actin antibodies were purchased from Santa Cruz
Biotechnology, Dallas, TX, USA. Alexa Fluor 594 goat anti-rabbit IgG and Alexa Fluor
647 donkey anti-mouse IgG were obtained from Life Technologies (Eugene, OR, USA)
4.3.2. NanoATV manufacture and particle characterization
P407-ATV was prepared by high-pressure homogenization using an Avestin Emulsiflex
C3 homogenizer (Avestin Inc; Ottawa, ON, Canada) [63, 82]. CF568-labeled P407-ATV
was prepared as described previously [53] using a 1: 4 (w/w) ratio of CF568-P407 and
P407. Drug content of the nanosuspensions were determined by reverse phase high82

performance liquid chromatography (HPLC) [105]. Particle size, polydispersity and zeta
potential for the nanoparticles were determined by dynamic light scattering using a
Malvern Zetasizer Nano-ZS instrument (Malvern Instruments Inc.; Westborough, MA,
USA).
4.3.3. Monocyte isolation, cultivation and HIV-1 Infection
Human peripheral blood monocytes were obtained by leukapheresis from HIV-1,2 and
hepatitis B seronegative donors and plated at a density of 1 x 106 cells/mL in Dulbecco’s
modified Eagle’s medium supplemented with 10% heat-inactivated human serum, 1%
glutamine, 50 µg/ml gentamicin, 10 µg/ml ciprofloxacin and 1,000 U/ml MCSF. After
seven days of cell differentiation, MDM were infected with HIV-1ADA at a MOI of 0.1
infectious viral particles per cell. After 4 hours the medium was removed and cells were
treated with 100 µM P407-ATV. Following 16 hours of drug treatment, the media was
replaced with drug-free fluids and cells were incubated for an additional seven days [57,
62].
4.3.4. SWATH-MS
MDM samples for mass spectrometry were collected seven days after infection and drug
treatment. Cells were washed with ice-cold PBS, scraped, pelleted, and stored at −80°C
until processed. Cell samples from four donors were processed simultaneously. Cell
pellets were re-suspended in cell lysis buffer containing 4% (w/v) SDS, 0.1 M
dithiothreitol (DTT) and 0.1 M Tris-HCl. Lysates were vortexed at room temperature for
10 min and then boiled at 95°C for 5 min to denature proteins. Protein quantification was
performed using the Pierce 660 nm protein assay (Thermo Scientific; Wilmington, DE,
USA) following the manufacturer’s protocol. On the basis of protein quantifications, 100200 µg of each sample was processed using filter aided sample preparation (FASP)
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[134-136]. Samples were denatured with urea exchange buffer (8 M urea, 0.1 Tris-HCl,
pH 8.5) placed into filter cartridges (10 kDa), centrifuged and then treated with 50 mM
iodoacetamide (Sigma-Aldrich). Trypsin (Promega; Madison, WI, USA) was added (2
µg/100 µg protein) and incubated at 37°C overnight on the cartridge. Eluted peptides
were dried via vacuum centrifugation. Peptides were cleaned using an Oasis mixed
cation exchange cartridge following manufacturer’s protocols (Waters Inc.; Milford, MA,
USA) and then dried under vacuum. After processing through mixed cation exchange,
peptides were subjected to further clean up using C18 Zip-Tips (EMD Millipore; Billerica,
MA, USA) and dried under vacuum. Peptides were resuspended in 0.1% formic acid
(Honeywell

Burdick

&

Jackson;

Muskegon,

MI,

USA)

and

quantified

using

NanoDrop2000 (Thermo Scientific). One µg of peptide was then prepared for SWATHMS quantitative proteomics analysis, as previously described [129, 137]. Samples used
to generate the SWATH-MS spectral library were subjected to traditional, datadependent acquisition (DDA).
4.3.5. Bioinformatics
Each SWATH-MS condition (per each donor) was transformed independently of other
conditions and comparisons between control condition and experimental conditions were
calculated. Extracted raw data transformation was performed as described by Haverland
et al. [129] The raw intensity for each protein was transformed by taking the natural log
(ln) of the intensity followed by assignment of z-score. The p-value for the computed zscore was assigned using standard normal distribution. Functional analysis and
signalling pathway representation were performed using an array of complementary,
open-access bioinformatic tools. Functional annotation of the proteins differentially
expressed was performed using the Database for Annotation, Visualization and
Integrated Discovery (DAVID) Bioinformatics Resources (6.7) and the Protein Analysis
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Through Evolutionary Relationships (PANTHER) Classification System (9.0), by entering
the UniProt sequence feature. The gene ontology (GO) annotations showed proteins
according to Biological Processes, Molecular Functions and Cellular Components.
Protein Class functional analysis was obtained by PANTHER. Protein–protein
interactions among all identified transcription regulators were investigated using Search
Tool for the Retrieval of Interacting Genes/Proteins (STRING) (9.1) considering a
confidence of greater than 0.4 (medium confidence). Unconnected proteins (orphan
proteins) and unconnected satellite networks (networks which were detached from the
largest network) were removed.
The complementary pathway analysis, Kyoto Encyclopedia of Genes and Genomes
(KEGG) was used to determine significant pathways between experimental conditions.
The KEGG pathway (71.0) for the phagosome was coloured using the KEGG mapper
colour pathway tool. Green represents all proteins confidently identified and red and blue
colours are assigned to up- or down-regulated proteins, respectively.
4.3.6. Antiretroviral activities
HIV-1 reverse transcriptase (RT) activity was measured to assess antiretroviral efficacy
in HIV-1 infected MDM. MDM were treated with 10, 100 or 250 µM native- or nanoATV
for 16 hours then infected with HIV-1ADA for 4 hours at a MOI of 0.1 immediately and five
and 10 days after drug treatment. Following viral infection, cells were cultured for an
additional seven days at which time cell media were collected for measurement of RT
activity. Briefly, in a 96-well plate, 10 µL of sample supernatants were mixed with 10 µL
of solution containing 100 mM Tris-HCl (pH 7.9), 300 mM KCl, 100 mM dithiothreitol,
0.1% NP-40 and water. The reaction mixture was incubated at 37˚C for 15 min and 25
µL of a solution containing 50 mM Tris-HCl (pH 7.9), 150 mM KCl, 5 mM DTT, 15 mM
MgCl2, 0.05% NP-40, 10 µL/mL poly(A), 0.25 U/mL oligo d(T) and 10 µCi/mL 3H85

thymidine triphosphate was added to each well; plates were incubated at 37˚C for 18
hours. Following incubation, 50 µL of cold 10% TCA was added to each well, the wells
were harvested onto glass microfiber filters and the filters were assessed for 3Hthymidine triphosphate incorporation by b-scintillation spectroscopy using a TopCount
NXT (Perkin Elmer Inc.; Waltham, MA, USA) [55, 62].
4.3.7. Western Blots
Protein expressions of Rab 5, 7 and 11, LAMP-1 and Actin were detected by Western
blot assays. MDM were treated with native drug or nanoATV and infected with HIV-1ADA
as described. Seven days after infection cells were collected and lysed using CellLytic M
Cell Lysis Reagent (Sigma-Aldrich). Protein content was quantitated using the Pierce
660-nm protein assay. Ten µg of protein was separated by electrophoresis using a
NuPAGE Novex 4-12% Bis-Tris gel (Life Technologies-Novex; Grand Island, NY, USA).
After electrophoresis, the proteins were transferred to a PVDF membrane (BioRad
Laboratories, Hercules, CA, USA) and then blocked with 5% non-fat dry milk in PBS and
0.1% Tween-20 (PBST). Membranes were probed with primary antibodies for Rab5,
Rab7, Rab11 or LAMP-1 and β-actin (Santa Cruz Biotechnology) followed by
horseradish peroxidase-conjugated secondary antibody (Life Technologies-Novex).
Proteins were detected using the SuperSignal West Pico Chemiluminescent substrate kit
(Thermo Scientific) [55, 81, 138].
4.3.8. Immunofluorescence and confocal microscopy
For immunofluorescence staining, cells were washed three times with PBS and fixed
with 4% paraformaldehyde (PFA) at room temperature for 30 min. Fixed cells were
permeabilized with 0.1% Triton in PBS and then blocked with 5% bovine serum albumin
(BSA) in PBS for 30 min. Cells were washed with 5% BSA in PBS and sequentially
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incubated with primary antibody against HIV-1 p24 (Dako; Carpinteria, CA, USA) and
either Rab5, -7, -11 or LAMP-1 (Santa Cruz Biotechnology) for 1 hour then washed 3
times with PBS. Secondary antibodies conjugated with Alexa594 or Alexa647 dyes (Life
Technologies-Molecular Probes) were applied against the primary antibody isotype and
incubated at room temperature for 1 hour then washed 3 times with PBS. Slides were
covered in ProLong Gold AntiFade reagent with DAPI (Life Technologies-Molecular
Probes) and imaged using a 40X oil lens on a LSM 510 confocal microscope (Carl Zeiss
Microimaging, Inc.; Dublin, CA, USA) [55, 139].
4.3.9. Cytokine Bead Array
MDM were infected with HIV-1ADA for 4 hours at a MOI of 0.1 then treated with 100 µM
native- or nanoATV for 16 hours immediately. 24 hours after drug treatment, 50 µL cell
culture media from treated and infected MDM were tested to determine the
concentrations of inflammatory cytokines measured by a cytokine bead array (CBA)
detection kit (Becton Dickinson Biosciences; Mississauga, ON, USA) and performed
according to instructions of the manufacturer. Monoclonal antibodies specific to
interleukin-12 (IL-12), tumor necrosis factor (TNF), IL-10, IL-6, IL-1b and IL-8 were
added to the samples in a 96 well plate. A serial dilution of known cytokines generated
the standard curve. Following three hours of incubation, all samples were acquired and
analysed on a FACSArray. The standard curve was determined using a parameter
logistics model and analysed with FCAP Array software. Cytokine levels are expressed
as pg/mL [140].
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4.4. Results
4.4.1. Proteomics analyses of HIV-1 infected MDM
HIV-1 infection engages a spectrum of cellular proteins seen in specialized cell
populations that support its replication [109]. The effect of nanoART on cell protein
expression has not yet been defined, in its target macrophage. To such ends, we applied
quantitative SWATH-MS proteomics followed by bioinformatics to uncover proteins
deregulated by free ATV or nanoATV with or without HIV-1 cell exposures. For these
experiments MDM were first infected with HIV-1ADA and four hours later medium was
removed and cells were treated with 100 µM P407-ATV. Following 16 hours of drug
treatment, the media was replaced with drug-free fluids and cells harvested for
proteomic tests after an additional seven days This experimental paradigm was followed
to assess the role that the antiretroviral delivery system had on macrophage proteome
during spreading viral infection. In attempts to separate the effects of the antiretroviral
drug, the nanoparticle and viral infection both separate and combined analyses of each
of these were required. Following biological assessments, cells samples were collected
and we assessed how nanoATV and free ATV could modulate virus-induced protein
changes. MDM were infected with HIV-1 at a multiplicity of infection (MOI) of 0.1 then
treated with 100 µM free or nanoATV. After seven days, cells were harvested and
SWATH-MS was performed on whole cell lysates [129]. Based on the expansive
proteomic data sets based on the biological response variables amongst the cell
treatments for nanoATV, ATV and HIV-1 illustrations of the data sets were divided into
replicate files and two independent figures. The first identified differnces between HIV-1
infected with or without nanoART and the second (with and without native ATV.
Quantitative profiling identified 527 significantly changed MDM proteins following HIV-1
infection. These were up- or down-regulated (p<0.05) assessed by paired-samples z88

scores. The numbers of proteins exhibiting changed expression in HIV-1-infected cells
were greater than in replicate infected cells treated with nanoATV, 527 versus 376
respectively (Figure 4.1A). Up- and down- regulated proteins in HIV-1 infected cells were
41 and 59% of total (n=216 and 311, respectively). In contrast for nanoATV-treated HIV1-infected MDM, up- and down-regulated proteins were 59 and 41% of total (n=222 and
154, respectively). Uninfected cells treated with nanoATV had fewer deregulated
proteins (n=195) compared to the other groups. The proteins uncovered engaged the
PANTHER database which sorted the deregulated proteins by classes. This illustrated
the relative numbers of proteins in each class for the HIV-1-infected and infected and
nanoATV-treated cells (Figure 4.1B). This showed that the number of deregulated
proteins in HIV-1-infected versus infected and nanoATV-treated cells was greater for
each of classes (nucleic acid binding, hydrolase, transferase, protease, signalling
molecule, transporter, transcription factors and ligases). These results demonstrate that
the deregulation of cellular proteins by HIV-1 infection can be altered by nanoATV
treatment. To uncover the function classes of proteins deregulated by HIV infection we
examined the functional categories by PANTHER classification. These data are based
on Gene Ontology annotations (GO molecular function, GO biological processes and
GO cellular component). Figure 4.2A shows the proteins sorted according to molecular
function with the percentages of total deregulated proteins classified for subgroups.
Common proteins were separated based on binding (28 to 31%), enzyme regulator (5%)
and transporter (3-4%) activities between the nanoATV, HIV-1 and HIV-1 and nanoATV
MDM. Proteins included Rab5, 7 (GDP/GTP and protein binding) and LAMP1 (enzyme
and protein binding) were joined. The classification revealed enrichment for metabolic,
cellular, localization, regulation and cellular organizational cellular processes. These
were the principal categories or protein sets (Figure 4.2B). The relative ratios for the
proteins were similar amongst groups. GO for cellular component showed that
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deregulated proteins sorted by cell organelle and macromolecular complex (Figure
4.2C). Note that such groupings were common to HIV-1 and HIV-1 and nanoATV cells.
The data, demonstrated that HIV-1 and HIV-1 and nanoATV affect similar cellular
processes. However, the numbers of proteins in each were reduced following infection
and nanoATV treatment.
4.4.2. KEGG pathway analyses for HIV-infected MDM
The proteins relative to functional pathways were further investigated using the KEGG
database, which, indicated phagosomes as one of the main pathways related to HIV-1
infection and nanoATV treatment. First we identified the role of HIV-1 infection as
compared to HIV-1 infected nanoART-treated MDM on the phagosome network (Figure
4.3A and B, respectively). Few numbers of proteins were deregulated with nanoATV
treatment. However, proteins were deregulated during HIV-1 infection and treatment
groups. Notably, there was an opposite regulation for proteins within the phagosome
and endosomal compartment between HIV-1-infected and HIV-1-infected and nanoATVtreated MDM. Up-regulation of Rab 5 and -7 proteins was observed in HIV-1 infected
cells; in contrast these same proteins were down-regulated in nanoATV-treated HIV-1
infected cells, pink = increased expression, blue = decreased expression). A similar
pattern for LAMP1 was also observed. Moreover, DAVID functional enrichment
clustering gave similar enrichment results for lysosomes in HIV-1-infected and HIV-1infected and nanoATV-treated cells by filtering the data sets at a P value <0.01. There
was a down-regulation of endosomal and lysosomal proteins in the group of uninfected
cells treated with native ATV (Figure 4.4A) or nanoATV. The latter showed few downregulated in parallel endosomal compartments (Figure 4.4B). HIV-1 infected MDM
treated with native ATV showed few altered proteins (data not shown). A composite of
these protein network changes are summarized in Table 4.1.
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4.4.3. Protein-protein interaction networks
To elucidate the operative and dynamic biological processes, methods depicting
changes of protein interaction networks are needed. Here we used our data from
SWATH-MS and applied it to the STRING bioinformatics tool to determine the dynamics
of the protein interaction after HIV-1-infection with or without nanoATV treatment.
Differentially expressed proteins in infected or infected and treated MDM were identified
using a P-value <0.05, and protein-protein interaction [141] networks were constructed.
The results of the networking reproduced a consistently high number of altered cellular
proteins by HIV-1 (Figure 4.5A). The complex changes and interactions during HIV-1
infection are clearly visualized and, more importantly, the reduced complexity is clear
when the infected cells are treated with nanoATV (Figure 4.5B). These dynamic changes
following HIV-1 infection and nanoATV treatment provide evidence of the importance of
antiretroviral therapy to control protein-protein interaction networks.
4.4.4. Antiretroviral activities of native and nanoformulated ATV
To confirm the antiretroviral activity of the nanoATV treatment the HIV-1 RT activity was
determined in native- or nanoATV-treated HIV-1-infected MDM. Cells were treated with
10,100 or 250 µM of native drug or nanoATV for 16 hours, followed by HIV-1ADA
challenge at an MOI of 0.1 at days 0, 5 and 10 after treatment. Infected cells were
cultured for an additional 7 days and RT activity in the culture medium was determined.
Significant differences were found between cells treated with native- or nanoATV. For
native ATV treated cells, RT activity was suppressed only in the day 0 infection group, at
all treatment concentrations. At 10 and 100 µM little antiviral suppression was observed
in the day 5 and 10 infection groups. In contrast, for cells treated with nanoATV, RT
activity was suppressed to less than 20% HIV-1 positive control with all treatment
concentrations and at all infection days (Figure 4.6)
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4.4.5. Endolysosomal proteins deregulated HIV-1 and nanoATV
We selected the proteins from the KEGG pathway related to phagosome and endosomal
compartment which were oppositely regulated by HIV-1 and HIV-1/nanoATV, (Rab 5, -7,
-11 and LAMP 1), for validation of the proteomics analysis. Protein expression of Rab 5,
-7, -11 and LAMP1 was determined by Western blot. As shown in Figure 4.7, there was
a down-regulation in Rab 5, -7, -11 and LAMP1 protein expression in nanoATV-treated
infected cells group. This effect was greater than that seen with native ATV treatment,
validating the KEGG analyses, and was time dependent, highlighting the dynamic nature
of endosomal trafficking based on macrophage differentiation, viral infection and
nanoparticle treatments. Notably, assay of Rab protein levels, at multiple days following
of HIV-1 infection and antiretroviral treatment revealed that nanoATV while inducing a
significant down-regulation of endosomal and lysosomal proteins the effects paralleled
what was observed in uninfected cells. Moreover, the downregulation was significant as
it was sustained over 10 days. To better assess the potential relationships between the
virus, Rab protein and nanoART we used immunofluorescence to visualize if colocalization

of

Rab7

or

LAMP1,

HIV-1

p24

and

nanoATV

could

occur.

Immunofluorescence co-localization (Figure 4.8) demonstrated that HIV-1 p24 (yellow),
Rab7 or LAMP1 cellular proteins and nanoATV were in the identical cellular locale.
These results highlight the fact that the endosomal trafficking routes taken by the virus
and the nanoparticles are identical. Most importantly the results support the idea that
HIV-1 and nanoATV while present in the identical subcellular locale influence endosomal
trafficking in opposite ways.
4.4.6. Cytokine profile for HIV-1 and nanoATV
To assess the activation state of the MDM, cytokine production was determined in
HIV-1 infected cells with or without nanoATV treatment. Cell culture media from
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nanoATV treated and untreated HIV-1 infected and uninfected MDM were incubated with
capture beads for IL-12, TNF, IL-10, IL-6, IL-1b and IL-8 and a detection fluorochromo.
Acquisition was performed by FACSArray cytometry. IL-12 and TNF were increased in
HIV-1 infected MDM. However, when the infected cells were treated with nanoATV
cytokine levels were reduced (Figure 4.9), implying a positive correlation with endosomal
and lysosomal proteins expression in our analysis mentioned above. NanoATV treated
infected macrophages also expressed higher levels of IL-6 and IL-8, compared to
infected and uninfected cells. There were no significant changes for IL-10 and IL-1b
(data not shown). These results showed a negative correlation in the expression of IL-12
and TNF between treated and untreated HIV-1 infected MDM, suggesting a role for
nanoATV as a regulator of pro-inflammatory cytokines.

4.5. Discussion
While it is well known that HIV-1 alters cellular nucleic acid binding and regulatory
protein functions affecting its transcription and translation [129, 142-144] how such virushost cell interactions are altered by nanoART is not understood [81]. To this end, we
used functional proteomics, cell biology and protein chemistry to investigate potential
interactions between the virus, the host cell and nanoART to elucidate how common
endocytic trafficking pathways can be engaged to both support viral replication and, at
the same time, affect its elimination. Endolysosomal pathways were uncovered and
found to be antagonistic in HIV-1 infected cells with nanoATV treatment. Notably, the
results highlight how the cell can be manipulated to either facilitate or inhibit viral growth.

The data also serves to highlight unique cellular processes engaged in both the viral
replication cycle and the means to attenuate it. Within an infected cell, virions are formed
in association with the cellular membrane. Initial investigations of HIV-1 assembly in
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macrophages were done through electron microscopy studies and suggested that new
virions were formed from the limiting membrane of a late endosomal compartment that
was linked to vesicle formations as is known to occur in multi-vesicular bodies (MVB) but
not at the plasma membrane known to be operative in T cells [113]. The linkage
between Endosomal Sorting Complex Required for Transport (ESCRT), MVB biogenesis
and viral budding is well known. In past years it was thought that HIV-1 budding is linked
to ESCRT through the presence of late endosomal markers associated with
macrophage-derived virions. However, the model has now been re-examined with
several recent reports show that the viral compartment has a neutral pH and can be
connected to the plasma membrane by micro-channels. [145-150]. We posit that the
virion trafficking and viral budding can be two independent but not mutually exclusive
pathways. Both are likely operative. First, we now show through cross validations of
proteomic, cell biology and protein chemistry is that the endolysosomal machinery is
significantly deregulated by HIV-1 infection and in opposite manner by nanoART
treatment. Second, there is a close association between endosomal-linked pathways
that include Rab5, -7 and -11 and viral infection. Third, the fact that this pathway is
conversely down regulated by HIV-1 infection likely reflects that the ability of the virus to
hijack ESCRT is augmented by the drug nanoparticles. Such a theory was previously
put forward in our own past works [81].

In regards to assembly and intracellular

accumulation of progeny HIV-1 we need not discount the elegant work performed by
immunofluorescence microscopy and immunoelectron microscopy that the organelles
are of an internally sequestered plasma membrane domain divergent from endosomes.
Both pathways can be operative in this scenario and are not mutually exclusive from one
another. Nonetheless, there is little question that virions are endosomal-associated.
Progeny virions are pulled down associated with these proteins and reverse
transcriptase activities are reduced significantly in parallel structures. While we did not
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study the tetraspanins CD81, CD9, and CD53, their regulation in phagocytosis or
intracellular trafficking is appreciated [151]. It is noted that CD81 is linked to activation of
mononuclear phagocytes, notably microglia [152]. Moreover, they are also involved in
the formulation of multinucleated giant cells [153] an additional major feature of viral
infection in macrophages. Rab proteins function to evade degradation and direct
transport to intracellular locations and utilize host vesicles to affect a stable intracellular
niche for microbial stability and longevity [154]. Thus, it is not surprising that HIV-1 would
induce these pathways. While the uninfected macrophages, the proteins are at the cell
surface and in intracellular vacuole-like structures with a complex content of vesicles and
interconnected membranes these compartments are in a dynamic state within the cell
and strongly regulated by HIV-1. While we acknowledge that endosome markers could
be recruited to the viral structures and incorporated into virions the dynamic process of
the virus and the macrophage transcends progeny virion assembly and includes viral
trafficking and transport mechanisms. Such observations combined with a broader
theory of the complexity of virus-cell interactions in the infected macrophages heralds
the notion that multiple events are operative for virion assembly and persistence [155].

NanoART enters the macrophages primarily through clathrin-mediated pathways
and is then stored in endocytic compartments. This provides a protected environment for
release of the drug to sites of viral growth. Compared with nanoART, the non-fromulated
native drug didn’t show similar trafficking behavior since less endolysosomal proteins
were found related to native drug treatment. On the one hand, amorphous native drug
can hardly be taken or stored by macrophage; on the other hand, native drug cannot be
internalized or carried by subcellular compartments for intracellular transportation.
Subcellular distribution of nanoformulated ART is in late and recycling endosomal
compartments. These same compartments serve as drug depots. Since late endosomes
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are sites of viral assembly, nanoART stored within such compartments can retain
significant antiretroviral activity. This was clearly demonstrated by the significant
reductions in HIV-1 RT activity previously observed in isolated endosomal compartments
in nanoATV treated HIV-1 infected MDM.
All together, the current studies suggest a mechanism whereby the endolysosomal
pathway is harnessed for HIV-1 viral replication and this same pathway may provide a
means for its elimination. Indeed, while it is known that HIV-1 traffics through Rab5, -7,
and -11 endosomal compartments how such early, late, and recycling endosomal pools
regulate stages of the viral life cycle are not understood [156]. Such an intersection
though is believed critical to the viral life cycle as the functions of the compartments
serve to maintain cell homeostasis and protein transport [157]. It has been reported that
Rab5 regulates clathrin-mediated endocytosis from the plasma membrane to early
endosome pools serve as an intersection point for proteins sorted to undergo
degradation through Rab7-dependent late endosome and lysosomal routes or be sorted
back to the plasma membrane through Rab11-dependent recycling pathways [156]. The
ability of the macrophage to overcome such degradation events at the subcellular level
underlie its abilities to persistent in its macrophage reservoir [156]. Moreover, it is well
known and accepted that Rab proteins function to evade degradation and direct
transport to intracellular locations and utilize host vesicles to affect a stable intracellular
niche for microbial stability and longevity. Similar mechanisms certainly parallel the
persistence of nanoART and sustained drug depots for extended time periods. Notably,
while proteomic tests revealed a large number of proteins deregulated by HIV-1 infection
and these were the same protein sets also affected by nanoART. The protein sets
included those affecting nucleic acid binding, hydrolase and enzyme activities,
oxidoreductase responses, and the cellular cytoskeletal backbone. These were all
characterized by GO molecular function that placed Rab5 and -7 proteins as those
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engaged in GTP catabolic processes, endocytosis and small GTPase-mediated signal
transduction pathways. The molecular functions for both endosomal-linked proteins are
GDP/GTPase activity and protein binding [158]. LAMP1 is associated with autophagy,
the establishment of protein localization to cell organelles, golgi to lysosome transport,
protein transport along microtubules and regulation of natural killer cell degranulation
cytotoxic activities. For the cellular component GO classification, LAMP1 is located at
the late endosome, lysosome, multivesicular body and vesicular exosome. It is included
in the group of enzyme and protein binding molecular function protein sets. Indeed, as
GO information, Rab family members are small, RAS-related GTP-binding proteins that
regulate vesicular transport. Each Rab targets multiple proteins that act in exocytic and
endocytic pathways.
An important finding in the current study was that Rab5, -7 and -11 and LAMP1
were significantly upregulated in expression following HIV-1 infection. HIV-1 could
induce those proteins linked to endosomes. While endosome markers could be recruited
to the viral structures and incorporated into virions the dynamic process of the virus and
the macrophage transcends progeny virion assembly but also viral trafficking and
transport mechanisms also strongly affected during the dynamic course of viral infection.
Interestingly, Rab 5, -7, -11 and LAMP1 deregulation in infected MDM was reversed, in
part, by nanoATV. The extent of protein deregulation in infected MDM was reduced by
nanoATV. As shown in some studies, Rab5 has a role in endocytosis and post-endocytic
trafficking [159]. Its activation promotes focal adhesion disassembly, migration and
invasiveness in tumor cells [160] and its knockdown decreases cell motility and invasion
by an integrin-mediated signaling pathway [161]. Moreover, it has been indicated that
Rab5, -7 and -11, affect RGS4 trafficking through plasma membrane recycling or
endosomes [158] and are used by the drug particles and the virus in a coordinated
manner. This was seen for other viral infections such as hepatitis B virus, which can
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affect Rab5 and -7 expression and use pathways for viral transport from early to mature
endosomes. This is a required step in the viral life cycle [162]. Similarly, in our study,
following endocytosis HIV-1 travels through the complex endocytic pathway networks to
reach the nucleus and initiate its replication and as such support the notion that
endosomal proteins play a critical role in the viral life cycle.

Interestingly, Rab5, -7 and -11 and LAMP1 were down-regulated in HIV-1 and
nanoATV-treated cells. This opposite regulation between HIV-1 and nanoATV in
regulation of endosomal proteins is likely important in that cellular trafficking pathways
and may also be involved in the release of infectious progeny virus.

As such late

endosome-associated Rab7A is known to be required for HIV-1 propagation, regulation
of Env processing and the incorporation of mature Env glycoproteins into viral particle
[163]. In addition Rab7A promotes Vpu interaction with BST2/tetherin to facilitate HIV-1
release [164]. This may also be operative for nanoparticle viral interactions and suggests
that in the present study nanoATV may disrupt mechanisms of critical cellular proteinprotein interactions harnessed during the viral life cycles to perpetuate its growth. In
other studies, silencing the expression of Rab9 inhibited HIV-replication [141] and
silencing the endogenous Rab11a GTPase expression could destabilize HIV-1 Gag and
reduce virion production both in vitro and in NOD/SCID/gc-/- mice [165]. It has been well
documented that Rab11 is located on pericentriolar recycling endosomes and plays a
key role in regulating vesicle trafficking through recycling endosomes to the plasma
membrane as well as in exocytosis [81, 114, 166]. Therefore, down regulation of Rab11,
as shown in our study, could destabilize HIV-1 proteins that would fail to traffic through
the endosomal compartments and could be redirected for degradation at the lysosomal
site.
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The deregulation of endosomal proteins suggests a new mechanism for viral
suppression by nanoART. This includes altered expression of endosomal proteins
resulting in parallel reductions in viral assembly sites. In addition, reduction of LAMP1
following nanoART treatment could reduce degradation of the nanoparticles and
therefore extend the half-life of ART. Our data is corroborated by studies demonstrating
co-localization of HIV-1 and endosomal and lysosomal proteins (Rab7 and LAMP1) [81,
167, 168]. Moreover, differences in cytokine profile expressions in untreated and
nanoATV treated infected HIV-1 macrophages suggest that nanoATV down regulated
the expression of pro-inflammatory cytokines. HIV-1 has been linked to the up-regulation
of cytokines and in fact HIV-1 Tat upregulates IL-12 and TNF-α and -β expression in
monocyte-derived dendritic cells [169, 170], suggesting an advantage of nanoATV in the
regulation of pro-inflammatory cytokines during HIV-1 infection. In contrast with
nanoATV, the effect of native ATV was relatively lower. Moreover, it has been reported
that IL-12 up-regulates Rab7 and induces lysosomal transport. Others have reported
that Rab proteins are regulated by cytokines and affect TNF secretion by activated
macrophages [171-173]. These findings provide further support to link Rab, IL-12 and
TNF expression. As HIV-1 virions assemble at the plasma membrane and recruit
endosomes to enable particle release, nanoATV depletes endosomal/lysosomal proteins
and deregulates pro-inflammatory cytokines thus controlling viral growth. Although a
mechanism is now forged to bridge nanoATV activities and endosomal signaling
pathways this study serves as only an entry to future investigations.
To this end, we are currently examining the possible signaling pathways
deregulated by nanoATV. Altogether, we found that SWATH-MS proteomics,
bioinformatics analyses and cell biology showed that nanoATV treatment of HIV-infected
MDM can down-regulate the endocytic proteins in HIV-1 infected cells and thus
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decrease the subcellular space available for viral assembly. Through this mechanism,
nanoATV has unique but real potential towards improving virus clearance. Our work
articulates commonly used pathways that are engaged in common macrophage
functions such as phagocytosis and vesicular trafficking that are used both by the virus
and the anti-virus.

4.6. Conclusions
HIV-1 and nanoATV deregulate cellular proteins in opposing manners. The common
pathways are linked to viral assembly and are endolysosomal-linked. Rab5, 7, 11 and
LAMP1 serve to coordinate molecular and biological functions of the virus and the
antivirus in subcellular compartments. Alterations made by HIV-1 and nanoATV indicate
that specific organelles are action sites for both. These findings provide novel insights
into the role played by long acting subcellular targeted nanotherapies for combating HIV1 infection.
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Figure 4.1. Deregulated proteins during HIV-1 infection and nanoATV treatment.
Uninfected and HIV-1 infected MDM were treated with or without nanoATV. The cells
were then collected for peptide identification. (A) Numbers of significantly up- or downregulated proteins were identified by mass-spectrometry based proteomics (SWATH101

MS) and compared to uninfected and untreated MDM used as controls. (B) Numbers of
proteins changed by PANTHER were classified according to protein class. These were
represented by 28 independent clusters (p<0.05).
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Figure 4.2. Functional characterization of significant deregulated proteins between
uninfected and HIV-1-infected and nanoATV treated MDM.
Proteins

were

compared

to

uninfected/untreated

control

cells

(p<0.05)

then

bioinformatics analysis was performed. The Gene Ontology molecular function (A),
biological processes (B) and cellular component distribution (C) were obtained from the
analysis using the Protein Analysis Through Evolutionary Relationships (PANTHER)
classification system.
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Figure 4.3. Schematic representation of the MDM phagosome network identified in
HIV-1-infected (A) and HIV-1-infected and nanoATV treated cells (B).
Proteins identified were compared against control uninfected MDM cultures (p<0.05).
The acquired profiles were analyzed through the bioinformatics program using a
comprehensive set of functional annotation tools to uncover biological data sets behind
the uncovered list of genes. This tool is titled Data for Annotation, Visualization and
Integrated Discovery (DAVID) facilitated the linked sets of enriched functional-related
protein groups. This tool was employed to identify enriched biological processes among
the expressed proteins. Gene Ontology terms were used to identify related pathways
with the assistance of the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database. The KEGG database facilitated the elucidation of the level functions for the
MDM as derived from the proteomic datasets. Statistical significance was determined
using a p-value < 0.05. Proteins in red and blue, display up- and down- regulation,
respectively. Proteins in green belong to the phagosome network and not deregulated by
ATV treatment.
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Figure 4.4. Changes in MDM phagosome network for uninfected cells treated
treated with nanoATV (A) or native ATV (B).
Proteins were compared to uninfected and untreated MDM controls (p<0.05) then
bioinformatics analysis performed following parallel procedures described in Figure 4.1.
Proteins in red and blue, display up- and down- regulation, respectively. Proteins in
green belong to the phagosome network but were not significantly altered by viral
infection or treatment.
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Figure 4.5. Protein interaction in HIV-1-infected MDM or nanoATV treated HIV-1infected MDM.
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Figure 4.6. NanoATV treatment effects HIV-1 reverse transcriptase (RT) activity.
HIV-1 RT activity was determined in treated (native ATV or nanoATV) MDM followed by
HIV-1 infection at days 0, 5 or 10. HIV-1 infected cells, without any treatment, served as
a positive control for RT activity. All samples were collected after 7 days of viral infection.
Results shown are the mean of 5 replicates.
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Figure 4.7. NanoATV and HIV-1 endosomal protein regulation.
Western blot of Rab5, -7, -11，LAMP1 and β-actin was performed in cell lysates from
MDM treated with native ATV or nanoATV and infected with HIV-1 at day 0, 5 or 10 postdrug treatment then incubated for 7 days. Uninfected cells and infected cells without
drug treatment served as negative and positive controls for differential expression of
cellular proteins during HIV-1 infection. Blots shown are from one donor and experiment,
and equivalent to two independent experiments performed.
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Figure 4.8. Subcellular localization of nanoATV, HIV-1 and endolysosomal proteins.
Cellular localization of Rab7 or LAMP1 endosomal compartments [51], HIV-1p24
(yellow) and nanoATV [174] are shown by confocal microscopy. Cell nuclei were stained
with DAPI (blue). Merged images showed the co-localization of all proteins.
Fluorescence images were acquired with a LSM 510 confocal microscopy, 400x
magnification.
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Figure 4.9. NanoATV regulation of cytokine profiles in HIV-1 infected MDM.
MDM were treated with 100 µM native ATV or nanoATV and infected with HIV-1 at day
0, 5 or 10 post-drug treatment. Untreated, uninfected cells were used as controls. After
24 hours of viral infection, cell culture media were collected and analyzed using a
cytokine bead array. (A) Density plots show expression of IL-12, TNF, IL-10, IL-6, IL-1b
and IL-8 for control, treated, HIV-1 infected and treated infected MDM. Cytokine levels
were detected by FACSArray cytometer and data was plotted using FlowJo (version
10.7) software. (B) Levels of IL-12 and TNF after treatment and infection are shown.
Data are analyzed using FCAP software and values of cytokine expression were
expressed as pg/mL.
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Table 4.1. Endolysosomal proteins in HIV-1, HIV+nanoATV, nanoATV and native
ATV treated MDM.
Deregulated (up- and down- regulated) proteins from the endolysomal (or phagosome)
pathway were grouped into early or late endosomes or lysosomes signalling. Z test
values were obtained after proteomics analyses. Up-, down- regulation or unchanged
protein expression are represented by red, blue and green arrow, respectively.
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Chapter V.
Small magnetite antiretroviral
therapeutic nanoparticle probes
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5.1. Abstract
Drug toxicities, patient compliance and limited penetrance into viral reservoirs have
diminished the efficacy of long-term antiretroviral therapy (ART) for treatment of human
immunodeficiency viral (HIV) infection. In response, cell targeted nanoformulated ART
(nanoART) was developed to facilitate drug adherence and improve disease outcomes.
However, rapid noninvasive determination of drug biodistribution in virus-target tissues
and reservoirs for nanoART have remained unrealized. To this end, small magnetite
ART (SMART) particles were made providing, for the first time, noninvasive
assessments of antiretroviral drug tissue distribution through magnetic resonance
imaging (MRI) techniques. Here, poly(lactic-co-glycolic acid), 1,2-distearoyl-sn-glycero3-phosphocholine

and

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy

(polyethylene glycol)-2000] encased particles were synthesized that contained
atazanavir (ATV) and ultra small paramagnetic iron oxide (referred to as magnetite).
Cellular uptake and retention of magnetite and ATV were first performed in human
monocyte-derived macrophages (MDM). Here tandem mass spectrometry showed that
SMART particles were efficiently taken up and retained in MDM. In mice, magnetite and
drug biodistribution paralleled one another, as readily seen after parenteral injections.
Three to one ratio of ATV to magnetite allowed drug assessments, for proof of concept
experiments, continuously up to 4 and again at 24 hours after particle injection. T2 maps
and 3D spoiled gradient recalled echo image sets confirmed rapid drug tissue
distribution in the reticuloendothelial system including spleen, liver, kidney and lung. At
four hours, T2 mapping showed predominant vascular particle distribution. However, by
24 hours signal intensity was seen in liver and spleen with little to no magnetite in
kidneys. Significantly, ATV tissue levels correlated with changes in tissue relaxivity
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(DR2=1/T2postinjection-1/T2preinjection). We conclude that SMART can facilitate the evaluation
of drug tissue concentrations in viral reservoirs and provide rapid assessments for the
next generation cell and tissue ligand decorated particles.

5.2. Introduction
Eradication of the human immunodeficiency virus type one (HIV-1) in its infected human
host will necessitate antiretroviral drug delivery to viral sanctuaries with the secondary
elimination of latent or restricted infections [75]. The former could be facilitated through
targeted nanoparticle drug delivery but, to achieve its potential, would require improved
virus-target tissue drug bioavailability. One major hurdle towards achieving this goal is
the dearth of any means to measure antiretroviral therapy (ART) distribution outside of
plasma drug levels [76]. We theorized that one way to achieve this is by combinations of
small magnetite particles and ART in a single nanoparticle. If realized, such small
magnetite ART (SMART) could permit rapid pharmacokinetic and pharmacodynamics
evaluations of ART in virus-target tissues, such as the lymph nodes and brain. Drug
biodistribution would readily be quantitated by a conventional magnetic resonance
imaging (MRI) scan. Such an approach would also provide the potential of delivering
packaged medicines to sites of limited viral growth and serve, in part, to eliminate the
viral reservoir. The approach was previously used for magnetically targeted cancer drug
delivery utilizing T2- or T2*-quantification by MRI [175-178].
To perform proof of concept studies on this theranostic approach we placed magnetite,
also referred to as superparamagnetic iron oxide particles, into lipid-coated polylactic-coglycolic acid (PLGA) nanoparticles with a commonly used antiretroviral protease inhibitor,
atazanavir (ATV). By combining PLGA and magnetite, organic/inorganic hybrid
composite biomaterials allowed combined diagnostics, or drug distribution assessments,
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with therapeutic ART delivery through a single MRI scan [80]. The SMART nanoparticle
testing was sped through the availability of in vitro cultivated monocyte-derived
macrophages (MDM) that determined optimal particle cell uptake and retention. This
facilitated studies of the dynamics of in vivo drug tissue distribution. All together, the
works provide the groundwork for the implementation of SMART systems for
noninvasive drug pharmacokinetics for the inevitable goal of viral eradication.

5.3. Materials and methods
5.3.1. Material preparation and characterization
PLGA,

1,2-distearoyl-sn-glycero-3-phospho-choline

(DSPC)

glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene

and

1,2-distearoyl-sn-

glycol)-2000]

(DSPE-

PEG2000) encased the SMART particle containing ATV and magnetite. The magnetite
particles were synthesized as follows: 6 mmol tris(acetylacetonato) iron(III) was mixed
with 30 mmol 1,2-hexadecanediol, 18 mmol oleic acid, 18 mmol olylamine and 60 mL
benzyl ether in a three-neck round-bottomed flask equipped with condenser, magnetic
stirrer, thermograph and heating mantle and stirred under nitrogen. The mixture was
slowly heated to 110oC and kept at that temperature for 1 hour, then slowly heated to
200oC. Reflux was kept after it reached 200oC for 2 hours, then slowly heated to 298oC
and kept at reflux for another 1.5 hours. After cooling to room temperature, a dark
homogeneous colloidal suspension was obtained. The suspension was precipitated in
ethanol with a magnetic field. The black precipitate was dissolved in hexane with the
presence of oleic acid and oleylamine and the solution was centrifuged at 3,800 x g for
10 min to remove any undispersed residue. The black solution was re-precipitated in
ethanol and centrifuged at 10,000 x g for 30 min. Solid products were obtained by drying
the precipitate under vacuum, generating the final dry particles.
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5.3.2. SMART composition and characterization
Preparation of the drug loaded DSPC/mPEG-DSPE shell and PLGA core particle was as
follows. First, a weighed amount of PLGA, ATV and magnetite were dissolved in
chloroform (oil phase) with a weight ratio of magnetite to ATV of 1:3. Second, the
aqueous phase was prepared by hydration of DSPC and mPEG-DSPE films. The oil
phase was added to the DSPC and mPEG-DSPE aqueous solution drop-by-drop with
constant stirring then sonicated for 60 seconds followed by a 20 second break under an
ice bath. This procedure was repeated for three cycles. Chloroform was then removed
by stirring overnight. Third, the particle suspension was centrifuged at 500 x g for 5 min.
The supernatant fluids were collected to remove the aggregated nanoparticles. A high
speed 50,000 x g centrifugation for 20 min was used to collect the nanoparticles. After
washing

twice

with

phosphate-buffered

saline

(PBS), the

nanoparticles

were

resuspended. SMART size and size distribution were measured by dynamic light
scattering (DLS, 90Plus, Brookhaven Instruments Co. USA) then diluted in ultrapure
water related to mass concentrations and dispersions. Fourth, the surface charge of the
SMART particles was determined by ZetaPlus, a zeta-potential analyzer (Brookhaven
Instruments Co. USA). The pH value and concentration of the particles dispersion were
fixed before measurements of zeta potentials. Fifth, the shape and surface morphology
of the SMART particles were investigated by transmission electron microscopy
performed as previously described [63]. Samples were prepared from dilutions in
distilled water of particle suspensions and dropped onto stubs. After air drying the
particles were coated with a thin layer of gold then examined by transmission electron
microscopy. The magnetic properties were determined by a Physical Property
Measurement System [179].
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5.3.3. SMART particle stability and release of drug in isotonic solution
SMART particles were dispersed in PBS and placed into a 10 k dialysis tube in 2 L PBS
under stirring at 37oC. At 30 min and 1, 2, 3, 4, 6, 8 and 10 days, 100 ml of the
suspension

was

collected.

The

supernatant

was

dissolved

in

100

µl

tetrahydrofuran/methanol (volume ratio 1:10) mixture. The amount of ATV and magnetite
was measured by high performance liquid chromatography (HPLC) and inductively
coupled plasma mass spectrometry (ICP-MS), respectively [63, 180].
5.3.4. SMART uptake and retention by MDM
Human monocytes were obtained by leukapheresis, from HIV-1 and hepatitis B
seronegative donors, then purified by counter-current centrifugal elutriation [106].
Monocytes were cultured in 6-well plates at a density of 1 x 106 cells/ml in DMEM
containing 10% heat-inactivated pooled human serum, 1% glutamine, 50 mg/ml
gentamicin, 10 mg/ml ciprofloxacin and 1,000 U/ml recombinant human macrophagecolony stimulating factor [57]. After 7 days of differentiation, MDM were treated with 100
mM SMART particles, (based upon ATV content). Uptake of SMART particles was
assessed without medium change for 8 hours. Adherent MDM were collected by
scraping into PBS, at 1, 2, 4 and 8 hours after treatment. Cells were pelleted by
centrifugation at 1000 x g for 8 min at 4oC. Cell pellets were briefly sonicated in 200 ml of
methanol/acetonitrile (1:1) and centrifuged at 20,000 x g for 10 min at 4oC. To determine
cell retention of SMART particles, MDM were exposed to 100 mM SMART particles for 8
hours, washed 3x with PBS, and fresh media without particles was added. MDM were
cultured for an additional 15 days with half medium exchanges every other day. On days
1, 5, 10 and 15 after SMART treatment, MDM were collected as described for cell
uptake. Cell extracts were stored at -80oC until HPLC analysis [63].
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5.3.5. Prussian blue staining of MDM retained SMART particles
MDM were treated with 100 mM SMART particles for 24 hours. Adherent MDM were
washed 3x with PBS. Cells were fixed with 2% formalin/2.5% glutaraldehyde in PBS for
10 min then washed 2x with PBS. Fixed macrophages were treated with 5% potassium
ferrocyanide/5% hydrochloric acid (1:1) for 10 min at room temperature. Following
solution aspiration the cells were washed 2x with PBS. Stained cells were examined by
light microscopy.
5.3.6. MRI phantoms and relaxivity measures
MDM were seeded onto 12-well plates at 1 x 106 cells/ml. After the cells reached 80%
confluence, the medium was changed to medium containing 100 mM SMART particles
(based on ATV content). Twenty-four hours later the treatment medium was removed
and the cells were washed 3x with 1 ml PBS. Cells were collected and suspended at
different cell concentrations (0-5 x 106 cells/ml) in 1% agar gel. T2-relaxtivity was
measured by MRI. Magnetite content in the cells was quantitated by ICP-MS.
5.3.7. SMART biodistribution
Biodistribution of SMART particles was determined in male Balb/cJ mice (Jackson Labs,
Bar Harbor, ME). SMART particles (30 mg/kg ATV) were injected via a jugular vein
cannula in a total volume of 100 ml for each mouse. The mice were scanned by MRI two
hours before injection then continuously at 0.25, 1, 2 and 4 hours or at 24 hours after
SMART administration. Tissues were collected following the final MRI scan. Tissue drug
levels were quantitated by ultra performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS) [181] and magnetite levels were determined by ICP-MS as
previously described [180].
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5.3.8. MRI acquisition
MRI was acquired using a 7T/16cm Bruker (Ettlingen, Germany) Pharmascan MRI/MRS
scanner and a commercial mouse body resonator. SMART detection by MRI was done
using T2 mapping for quantitation and T2* weighted high resolution imaging for detection
of biodistribution throughout the body. The sequence used for T2 mapping was a CPMG
phase cycled multislice multiecho sequence. Forty-one 0.5 mm thick contiguous
interleaved coronal images were acquired with an acquisition matrix of 256 x 192, 40
mm field of view, 12 echoes at 10 ms first echo time and 10 ms echo spacing, repetition
time of 4680 ms, three averages, for a total acquisition time of 30 min. T2* weighted MRI
was acquired using a 3D spoiled gradient recalled echo sequence with echo time = 3 ms,
repetition time = 10 ms, 15 degree pulse angle, 50 x 40 x 30 mm FOV, 256 x 196 x 128
acquisition matrix, six averages, for a total scan time of 25min.
5.3.9. MRI analyses
T2 maps were reconstructed using custom programs written in Interactive Data
Language (IDL; Exelis Visual Information Solutions, McLean, VA). Preinjection and 24
hour postinjection maps were constructed using the even-echo images from the CPMG
phase cycled imaging data set. Mean tissue T2 was determined using region of interest
[164] analyses before and after SMART injection for the 24 hour results. Magnetite
concentration was then determined from the change in relaxivity (DR2 = 1/T2preinjection 1/T2postinjection) and the per milligram magnetite of SMART particle relaxivity (r2)
determined as the slope of magnetite concentration versus R2 in phantom studies.
Acute (0-4 hour) data were acquired with in-magnet jugular vein injection, allowing
sequential T2 mapping to be acquired with a T2* weighted FLASH image acquired at the
end of a four-hour period. The natural coregistration of these data allowed development
of magnetite concentration maps based on relaxivity changes using custom programs
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written in IDL for the acute scanning session. The ROI analyses were performed using
ImageJ (http://imagej.nih.gov/lj) software. For analysis of the acute study, the windows
synchronize option was used to simultaneously draw ROIs at same locations on all
concentration maps at different time points.
5.3.10. Immunohistochemical identification of cell-SMART uptake
To determine cell localization of SMART spleen and liver were collected after the final
MRI scan and fixed in 10% neutral buffered formalin. Tissues were paraffin embedded
and sectioned at 5 µm. To identify macrophages, sections were incubated with antibody
to ionized calcium binding adaptor molecule 1 (Iba1, Wako Chemicals USA, Inc.,
Richmond, VA). The polymer-based HRP-conjugated anti-mouse and anti-rabbit Dako
EnVision were used as secondary detection reagents and color developed with 3,3'diaminobenzidine (DAB). All paraffin-embedded sections were stained with Prussian
blue to identify magnetite content. Slides were imaged using a Nuance light microscopy
system for brightfield imaging.

5.4. Results and discussion
5.4.1. SMART development and in vitro evaluation
The schematic structure of SMART is represented in Figure. 5.1A. This is composed of a
hydrophobic PLGA/ATV/magnetite core and an amphiphilic DSPC and DSPE-PEG2k
lipid shell. DSPC and DSPE-PEG2k increased SMART stability and facilitated increased
systemic formulation circulation times. Both ATV and magnetite are distributed
homogeneously within the core of the particle. SMART was made using a single oil-inwater emulsion with lipid surfactants. After sonication amphiphilic lipids self-assembled
to the monolayer surrounding PLGA/ATV/magnetite containing oil droplets, achieved
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through hydrophobic interactions. Evaporation of chloroform under continuous magnetic
stirring allowed for the formation of lipid-coated solid PLGA/ATV/magnetite core. SMART
was then purified by ultracentrifugation before further characterization. Our DLS results
showed that the average size of the particles is 268 nm with a polydispersity of 0.2. The
narrow size distribution is linked to the DSPC, which serves to stabilize the polymeric
SMART in the aqueous phase. The zeta potential of the particles is -45.2 mV, which
provides its stability when suspended in aqueous media. Although DSPC is neutral when
it is used as a particle coat it exhibits non-zero mobilities in an external electric field. This
may result in a higher negative charge since some anions bind to the neutral lipids
making the surface more negatively charged. Transmission electron microscopy (TEM)
was employed to obtain the image that best reflects SMART particle morphology
(Figure. 5.1B, right panel). This illustrated that the particles were spherical in shape with
narrow size distributions. A representative particle is shown by TEM, showing the ultra
small iron oxide contained within the particle’s core.
Our preliminary in vitro results showed that SMART is very stable and ATV can slowly
release from SMART up to 10 days. After SMART particle characterizations were
completed, the in vitro kinetics of MDM uptake and retention were determined. Our
previous studies of nanoART uptake in MDM showed that > 95% of total uptake occurs
by 8 hours for ATV nanoART [62, 63, 82, 182]. Up to 2 mg of ATV/ 106 cells was
recorded in MDM at 8 hours with magnetite uptake reflective of particle composition
(Figure. 5.1C). The majority of the cells took up the magnetite as observed through
Prussian blue staining (Figure. 5.1D). Indeed, such staining demonstrated that
magnetite-containing particles were readily incorporated in macrophages by 8 hours.
The controlled and sustained release profile or ATV facilitates the application of the
SMART particles for the delivery of antiretroviral drugs.
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5.4.2. Measures of SMART particle relaxivity (r2)
Concentration dependent relaxivity [r2 (s-1 ml mg-1)] causing increased relaxivity (R2 (s-1))
in tissue as a function of concentration (expressed as mg/ml magnetite) of SMART
particles were determined using phantoms consisting of both free SMART particles
(Figure. 5.2A) and SMART particles taken up by MDM (Figure. 5.2B). The magnetite
concentrations in mg/ml contained by SMART in 1% agar gels were plotted against R2
as measured by MRI. The relationship between R2 and magnetite concentration of
SMART in phantoms was linear within the range of the measured magnetite
concentrations. The concentration dependent relaxivity of SMART was found to be r2 =
6200.2 (s-1 ml mg-1) in MDM and r2 = 7052.1 (s-1 ml mg-1) in PBS. The r2 of SMART in
MDM was used for noninvasive in vivo quantitation of magnetite concentration due to
SMART influx using MRI.
5.4.3. Real time SMART biodistribution and pharmacokinetics
Magnetite labeling allows MRI to be used to quantify the distribution of SMART particles
over time in live animals. This can be seen in Figure. 5.3. Figure. 5.3A shows examples
of magnetite concentration (from magnetite in SMART) constructed from MRI T2 maps
measured before and continuously every 30 minutes for four hours after SMART
injection. ROI analyses of these data from six animals are shown in Figure. 5.3B. It can
be appreciated from the images that a significant amount of the SMART is still within the
vasculature, largely leading to the intensity in the kidney, as kidney shows very little
uptake by 24 hours. This reflects the measured concentration in kidney reducing over
the first four hours while in liver and spleen, organs where SMART accumulates, the
mean signal is relatively constant or increases as the particles redistribute from the
blood to the tissue. Significant accumulation of SMART was found in liver and spleen at
4 hours as can be appreciated in Figure. 5.4. Figure. 5.4 displays two of the 0.128 mm
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thick T2* weighted high resolution 3D FLASH images of the same mouse before and 4
hours after injection of SMART. Presence of magnetite in tissue causes a reduction of
T2* to the point of complete signal loss at TE = 3 ms in the liver, spleen, and some
abdominal regions. This method is not quantitative, however it does allow ready
identification of the presence of magnetite throughout the body which can be used to
guide quantitative ROI analyses using T2 maps.
5.4.4. Correlation between magnetite and drug tissue content
Figure. 5.5 shows the relationship between magnetite concentration and ATV
concentration of liver, spleen and kidney in four animals 24 hours after injection. It can
be appreciated that there is a significant positive correlation (Pearson Correlation,
r=0.786, p=0.0008). These results demonstrate the capability of MRI to be used for
monitoring nanoART distribution.
5.4.5. Identification of magnetite-ART relationships in systemic tissues
We reasoned that cellular biodistribution of SMART was concordant with our prior results
with nanoART [183]. To prove this theory we next studied the relationships between
SMART particle biodistribution and macrophages in mice following parenteral SMART
injections. Animals were sacrificed 4 hours after injection and tissues collected. Dual Iba1 (for macrophages) and Prussian blue staining (for magnetite) were performed and
evaluated by brightfield microscopic imaging. Prussian blue staining was nearly
exclusively in tissue cells identified as macrophages. As shown in Figure. 5.6, Iba-1+
macrophages were readily seen in both liver and spleen in parallel to distribution of
Prussian blue. The dual staining pictures showed that the SMART particles were
retained in tissue macrophages. Erythrocyte hemoglobin and its breakdown products are
a substantive source of iron. These are degraded after the lifespan of the erythrocyte
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[38]. This occurs predominantly in the spleen with iron transferred back into the blood.
The highly vascularized spleen contains easily seen red blood cell breakdown products
including iron that are phagocytized by macrophages [34]. Thus, the total iron content in
the spleen is readily visualized by Prussian blue staining but substantively increased
after SMART treatments (Figure. 5.6G and H). The iron content in spleen also changed
from 228 µg/g before treatment to 356 µg/g after treatment, measured by ICP-MS. This
also explains why background MRI scans are darkened in the spleen but increased after
injection of SMART particles.

5.5. Discussion
Our laboratories are responsible for the development of cell-based carriage and delivery
of antiretroviral drugs to sites of active HIV-1 replication [63, 82, 95, 106, 182, 184, 185].
This so-called “Trojan Horse” macrophage drug delivery scheme takes full advantage of
the cells’ substantive endosomal storage capacity, its phagocytic and secretory functions,
and its high degree of mobility to facilitate drug delivery [81]. As the macrophage is a
principal cell target for viral growth, the added benefit rests in the abilities to bring ART to
subcellular sites of viral assembly [186]. Such a system when used as a weekly or
monthly parenteral injection has previously been shown to hold significant gains over
conventional native oral drug therapeutic regimens [184, 185].
The principal goal in developing this polymer system rests in the ability to utilize MRI
scans to rapidly assess cell and tissue drug biodistribution. The idea is that the polymerencased dual magnetite and drug particle would permit a clear determination of drug
levels in virus-target tissues in a very short time interval (hours). As plasma drug levels
remain the gold standard for pharmacokinetic testing this technology clearly opens new
opportunities to develop platforms that would accelerate elimination, or some day cure,
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of viral infections. Notably, there is a considerable focus amongst HIV/AIDS researchers
towards the development of any or all reliable methods to bring drugs to reservoir sites
with the explicit goal of eliminating virus. Targeted drug as well as gene delivery when
combined with suitable imaging techniques could facilitate this goal by providing a “go/no
go” for treatment success [63]. Although this is the first time such “theranostics” has
been applied for HIV diagnosis and therapies, similar systems have been developed in
recent years for cancer treatments [187]. Here, the application is for early diagnostics.
The unique payloads of nanomaterials include fluorescent semiconductor nanocrystals
(quantum dots) as well as magnetic nanoparticles as developed in this report.

All

provide properties that can facilitate in vivo imaging with the help of MRI tests as well as
fluorescence based approaches [188]. In all, interest in this idea will likely continue to
grow through the development of carrier nanoparticles designed to target specific tissue
and effect local chemo-, radio- and gene- directed antiretroviral or immune modulatory
therapies [189].
Liposomes and polymer nanoparticles are the two major types of nanoparticles that have
been developed and evaluated for diagnostic and therapeutic purposes. Liposomes
composed of natural lipids are attractive DDS because of their high biocompatibility, low
immunogenicity, long systemic circulation and favorable pharmacokinetic profile.
Specific targeted delivery can easily be achieved by conjugating a targeting ligand to the
lipid molecule [190-192]. Several liposomal drug formulations have been approved by
FDA for clinical application, such as Doxil and DaunoXome [190, 192, 193]. However,
the possible intrinsic low drug loading capacity, fast release profiles of hydrophobic
drugs and physical instability of liposomes limit their clinical applications of different
drugs [194]. Polymeric nanoparticles composed of synthetic PLGA are another widely
developed/studied drug delivery platform because of their high stability, relatively high
drug loading capacity of all kinds of drugs, biodegradability, low toxicity, and
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controlled/sustained drug release profiles. Depending on particle composition, the drug
release profiles of PLGA nanoparticles can be modulated to be within days, weeks or
even months [195-197]. However, the biocompatibility/immunogenicity of nanoparticles
composed of synthetic polymers including PLGA is not as high as liposomes. Without
further chemical modification, PLGA nanoparticles are rapidly removed from circulation
by the mononuclear phagocyte system (MPS), resulting in short systemic circulation
[194]. In summary, both liposomes and PLGA nanoparticles are not independently
structurally robust platforms. Thus, lipid-coated polymer nanoparticles, formed by
combining synthetic polymers and natural lipids, have been developed as robust drug
delivery platform to combine the advantages and avoid the disadvantages of liposomes
and polymer nanoparticles [198, 199].
The visualization of cellular function in living organisms is not a new modality [106, 200,
201]. Optical, X-ray, nuclear, MRI and ultrasound allows three-dimensional whole-body
scans at high spatial resolution and are adept at morphological and functional
evaluations. The data obtained can be enhanced by magnetite and improved image
resolution. By immobilizing a specific target molecule on the surface of a magnetic
particle, the molecule inherits its magnetic property. Magnetic tissue targeting using
multifunctional carrier particles can also facilitate effective treatments by enabling sitedirected therapeutic outcomes. To this end, we selected DSPC and DSPE-PEG2k as the
shell and PLGA as the core of SMART system. DSPC is used to increase the
biocompatibility of SMART, and DSPE-PEG2k is used to build a sterically repulsive
shield around SMART that reduces opsonization, prevents interactions with the MPS,
escape renal exclusion, and increases systemic circulation. To the best of our
knowledge, this is the first attempt to develop lipid-coated PLGA nanoparticles for HIV
therapeutics. Our current work sought to use lipid coated PLGA SMART to encase
magnetite and antiretroviral therapy to facilitate MDM uptake of drug and its subsequent
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slow release. The long-term goals are straightforward. One is to use the synthesized
SMART to facilitate drug screening for specific targeting ligands or sugars. The second
is to determine the distribution of nanoART in viral reservoirs for the ultimate eradication
of HIV. Our in vivo MRI results clearly demonstrated that SMART could facilitate the
noninvasive evaluation of drug pharmacokinetics and biodistribution in different tissues,
and provide rapid assessments for the next generation cell and tissue ligand decorated
particles. This initial study lays the groundwork for what will quickly follow and ultimately,
we believe, lead to an effective means to combat and potentially eliminate HIV disease.

5.6. Conclusions
We posit that SMART particles can be developed for noninvasive evaluation of drug
distribution and pharmacokinetics. These particles show clear potential in allowing a
rapid evaluation of ART content in viral reservoirs that include the brain and lymphoid
tissues. Improve in particle delivery have been seen in cell and tissue targeted particles
with coated ligands and sugars for future viral elimination studies.
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Figure 5.1. Development of SMART nanoparticles.
(A) The schematic structure of lipid-coated PLGA SMART. ATV and SPIO are well
distributed within the PLGA matrix to form the core of SMART. The PLGA core is coated
with lipid monolayer to form the shell of SMART. (B) Representative transmission
electron micrograph (TEM) of a single SMART particle. (C) Timecourse of uptake (upper
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panel) and retention (lower panel) of SMART in MDM., MDM were treated with 100 mM
SMART (based on ATV content) for 1, 2, 4 and 8 hour uptake studies. For cell retention
MDM were treated with 100 mM SMART for 8 hours, cell culture media was changed
and cells were cultured for an additional 15 days. The cell lysates at indicated times
were analyzed by HPLC and ICP-MS for ATV and magnetite quantification, respectively.
Data represent the mean ± SEM, n = 3, for each time point. (D) Prussian blue staining of
MDM. MDM were treated with PBS (negative control, upper panel) or 100 mM SMART
(lower panel) for 24hours, and then fixed with 2% formalin/2.5% glutaraldehyde and
stained with 5% potassium ferrocyanide/5% hydrochloric acid (1:1).
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Figure 5.2. Concentration dependence of relaxivity (r2) of SMART in (A) PBS and
(B) MDM.
MDM were incubated with 100 µM SMART (based on ATV content) for 24 hours.
Collected MDM and SMART were suspended in 1% agar gel. T2 was measured by MRI
and magnetite content by inductively coupled mass spectrometry (ICP-MS).
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Figure

5.3.

MRI

assessments

of

the

tissue

drug

biodistribution

and

pharmocokinetics by SMART particles.
After pre-MRI scan, mice were injected with SMART through a jugular vein cannula, and
then scanned by MRI at continuously at 30 minute intervals up to 4 hours after SMART
administration. Mean tissue SMART content was determined as detailed in Materials
and Methods. Immediately after the final scan, mice were euthanized and tissues were
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collected for ATV quantification by UPLC-MS/MS. (A) MRI based images of magnetite
concentration in kidney, spleen and liver from 0.5 h to 4 h following SMART
administration. (B) Mean ± SEM (n=6) of magnetite levels in kidney, spleen and liver
over 4h following SMART administration.
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Figure 5.4. 3D gradient recalled echo images of the same mouse before (A) and 4
hours after (B) injection of SMART.
It can be appreciated that the signal from the liver is completely eliminated due to the
accumulation of magnetite loaded SMART (L=lung, Lv=liver, K=kidney and S=spleen).
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Figure 5.5. Correlation of SMART-associated magnetite and ATV in tissues 24
hours after administration.
The magnetite concentration was quantified from the change in T2 weighted relaxivity
(DR2 = 1/T2preinjection - 1/T2postinjection) and the per milligram magnetite relaxivity (r2)
determined as the slope of magnetite concentration versus R2 in SMART phantom
studies. ATV concentrations were quantified by UPLC-MS/MS following the final 24 hour
MRI scan.
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Figure 5.6. Immunohistology of Iba-1 staining and Prussian blue staining.
(A) Liver from control mice with Prussian blue (200×). (B) Liver from SMART treated
mice with Prussian blue (200×). (C) Liver from SMART treated mice with Prussian blue
and Iba-1 (200×). (D) Enlargement from indicated section in C. (E) Spleen from SMART
treated mice with Prussian blue (200×). (F) Spleen from SMART treated mice with
Prussian blue and Iba-1 (200×). (G) Enlargement from indicated section in F. (H) Spleen
from control mice with Prussian blue and Iba-1 (400×). Livers and spleens were fixed
with 10% formalin, paraffin embedded and sectioned for immunohistological analysis
after the final MRI scan. Macrophages were identified by Iba1 stains (brown) and
magnetite identified by Prussian blue. Fl=lymphoid follicle, M=marginal zone.
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Chapter VI.
Conclusions and Future
Directions
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Our laboratory has developed nanoART for improved formulation stability and
bioavailability, higher intracellular drug concentrations, and sustained in vivo drug
release. It has realized long-acting antiretroviral therapy for types of hydrophobic
antiretroviral drugs. In this study, we focused on hydrophilic nucleoside reverse
transcriptase inhibitor—lamivudine. A hydrophobic 3TC prodrug was successfully
synthesized through myristoylation and incorporated into targeted and non-targeted
nanocrystalline formulations to improve drug half-life and reduce cytotoxicity. NMTC
exhibited enhanced macrophage uptake and sustained antiretroviral efficacy. FA-NMTC
exhibited improved pharmacokinetics and this novel drug delivery system has shown
great potential for clinical application. In our subcellular trafficking study, we found
macrophages could act as carriers of nanoART to improve drug bioavailability. Late and
recycling endosomes are depots for both drug particle and HIV, and nanoATV and HIV-1
utilize similar subcellular pathways. SWATH-MS profiling broad the understanding of
complex nanoART-HIV interactions. HIV-1 and nanoART deregulate cellular proteins in
opposing manners and specific organelles are action sites for both. Rab5, 7, 11 and
LAMP1 serve to coordinate molecular and biological functions of HIV-1 and drug
particles. Besides, we developed SMART particles for noninvasive evaluation of drug
distribution and pharmacokinetics. These studies unveil a broader understanding of
nanomedicine for antiretroviral therapy and exhibit great potential in its future clinical
applications.
Overall, this project has exhibited the great potential of our nanoformulated antiretroviral
drug delivery system in the clinical applications. In the future, all types of antiretroviral
drugs can take advantage of this system for improved antiretroviral efficacy and
pharmacokinetics. Besides folic acid, different targeting ligands will be developed and
utilized for nanoformulation development, which will uncover new mechanisms for longacting antiretroviral therapy.
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